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CHAPTER 1 
INTRODUCTION 
Individuals with Major Depressive Disorder (MDD) frequently experience cognitive 
decrements as part of the illness. Ironically, medications used to treat depression may have a 
positive effect on some aspects of cognition but may adversely affect others. Understanding the 
relative cognitive costs of medications is imperative for considering treatment of patients in a 
variety of circumstances. Cognitive side effect profiles of antidepressant medications for 
depression must be carefully distinguished from the adverse cognitive effects of depression per 
se. Unfortunately, few studies evaluating cognitive profiles of psychotropic medications directly 
compare unmedicated and medicated adults with clinically significant depression; those that do 
are generally troubled by methodological problems such as very small samples and mixed 
samples of medicated and unmedicated patients with depression.  
One fundamental challenge in studying the effects of medications for depression is that 
psychotropic research is most frequently conducted on healthy adults. These methods are 
continually used despite evidence that side effect profiles based on non-depressed adults may not 
generalize to depressed adults, especially those with the most severe symptoms who are most 
likely to benefit from psychotropic treatment (Fournier et al., 2010; Kirsch et al., 2008). Until 
more is known about the beneficial and adverse effects of antidepressant medications on 
cognition among adults with clinical depression, research and clinical interventions cannot be 
formulated on sound empirical bases. Accordingly, the present study compares cognitive 
functioning profiles among unmedicated adults with MDD (uMDD), adults with MDD on 
therapeutic levels of antidepressant medications (mMDD), and healthy comparison (HC) 
participants.  
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Debilitating Symptoms of Depression  
Major Depressive Disorder (MDD) is the most prevalent psychiatric disorder, with an 
estimated lifetime prevalence of 13 to 21% and an incidence rate of 5 to 7% in the United States 
(Kessler & Walters, 1998; Turner & Gil, 2002; Hasin et al., 2005; Alonso & Lépine, 2007; 
Kessler et al., 2005; Murphy et al., 2000). Within the framework of affective disruptions of the 
disease, individuals with MDD are also likely to experience impairments in several domains of 
cognitive functioning (Purcell et al., 1997; Porter et al., 2003; Ravnkilde et al., 2004). These 
affective and cognitive processing weaknesses may contribute to an increased risk for the 
alarming rates of suicide among people with depression. Currently, patients with MDD account 
for 60% of suicides in the United States each year (NIMH, 2009).  
Individuals living with MDD experience hallmark symptoms of sadness and/or 
anhedonia, in addition to signs of withdrawal, fatigue, sleep disruption, anxiety, and decreased 
self-worth. These individuals may also face difficulties upholding responsibilities within the 
household and workplace, and struggle to establish and maintain close relationships (Godard, 
Grondin, Baruch & Lafleur, 2011; see Papakostas et al., 2004 for review). Many patients likely 
experience both state-specific cognitive effects from symptoms of a current episode as well as 
cumulative cognitive effects from chronic years with depression (Austin et al., 2001; Castaneda 
et al., 2008; Papakostas et al., 2004; Schmid et al., 2011). Furthermore, the effect of depression 
on certain cognitive domains (e.g., verbal memory) appears to be worse for individuals in 
recurrent episodes than for those experiencing a first episode (Fossati et al., 2004; Sweeney et 
al., 2000). 
Debilitating Effects of Depression on Cognition 
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Among the debilitating psychological symptoms of depression are the demonstrated 
deficits in several domains of cognitive functioning. The field of neuropsychology has 
traditionally viewed depression as associated with potentially reversible cognitive deficits that 
can fade during episode remission or after treatment (Sobow et al., 2006; Burt et al., 1995). 
However, cognitive decrements during depression may not be as universal or reversible as once 
thought. First, not all individuals with depression exhibit symptoms of cognitive dysfunction. 
Furthermore, for the patients who do exhibit these decrements, cognitive difficulties in attention 
and executive functioning often remain during remission from depressive symptoms (Iverson et 
al., 2011, Paelecke-Habermann, Pohl, & Leplow, 2005; Weiland-Fiedler et al., 2004).  
Despite the literature that consistently suggests that patients with depression endure 
cognitive deficits, there are inconsistencies in the breadth of affected areas. There is some 
consensus that, at minimum, the areas of executive functioning, psychomotor functioning, and 
memory are adversely affected during MDD (Egeland et al., 2005). Theories suggest that 
differences in cognitive functioning within the depressed population may vary as a function of 
cortisol levels, depressive subtype, ascertainment status (inpatient, outpatient, volunteer), 
severity and/or use of psychotropic medication.  
A limited body of research suggests that patients who are successfully treated using 
selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCA) have better 
cognitive functioning than do their unmedicated counterparts (Gualtieri et al., 2006). A 
comparison of healthy adults and unmedicated depressed patients is therefore a strong method 
for examining cognitive deficits endured due to depression, in the absence of medication effects 
on cognitive functioning. Table 1 (see Appendix A) summarizes six studies that are the main 
sources of empirical information focused specifically on unmedicated adults with MDD. As 
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shown in the table, the literature evaluating cognitive functioning in unmedicated depressed 
adults is limited. The dearth of information on unmedicated adults with depression likely reflects 
that most patients are psychotropically treated without delay (i.e., prior to enrollment in research, 
especially longitudinal study). Furthermore, the few studies that include unmedicated depressed 
patients typically do not evaluate the group separately from medicated patients when examined 
in reference to a healthy comparison group. When unmedicated depressed patients are studied, 
they are too often combined with medicated depressed patients, therefore confounding the 
assessment of direct effects of depression on cognition with those associated with antidepressant 
drugs. In addition, late-phase studies of medication effects rarely include measures of cognitive 
functioning, as budgetary emphasis is placed on obtaining a large enough sample size to power 
studies to separate active from placebo antidepressant effects. Separately examining medicated 
and unmedicated groups would systematically separate the cognitive deficits experienced in 
depression not complicated by the use of the psychotropic medication treatments.  
As indicated in Table 1, limited findings available suggest that healthy adults outperform 
unmedicated depressed patients in the areas of attention, inhibition, concentration, executive 
functioning, and psychomotor functioning (Porter et al., 2003; Grant et al., 2001; Den Hartog et 
al., 2003; Langenecker et al., 2007; Gualtieri et al., 2006; Bulshman et al., 2006). Findings in the 
areas of working memory, visuospatial memory and verbal learning memory, however, were 
more variable (Den Hartog et al., 2003; Grant et al., 2001; Gualtieri et al., 2006; Porter et al., 
2003). Inconsistency across studies depending on the cognitive domain indicates potential 
methodological limitations. An important weakness of these studies is their use of small samples 
and that they neglect to provide effect sizes; therefore, concern about insufficient power clouds 
interpretation of null findings as evidence for equivalence of unmedicated depressed patients and 
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their healthy adult counterparts.  
Potential Debilitating Effects of Antidepressant Medication on Cognition 
The effects of antidepressant medications on cognition are an important, yet surprisingly 
understudied question. Moreover, the limited extant literature evaluating this question may be 
restricted because antidepressant effects on cognitive functioning has been conducted by 
producers of the pharmacological agents and infrequently by neuropsychologists. Because these 
evaluations are not typically conducted from a neuropsychological perspective that includes 
comprehensive assessment of cognitive domains of executive functioning, attention, 
concentration, psychomotor speed, working memory and verbal and visuospatial memory, a 
thorough understanding of cognitive effects of antidepressant medications remains unknown. 
Most studies of antidepressant side effects investigate safety and tolerability on small samples of 
healthy adults (e.g., 10-15 participants), completed as part of Phase I trials (Klein, 1991). Phase 
II trials aim to examine short-term safety and tolerability for patients with the disorder. These 
trials also typically employ small sample sizes and often work within the constraints of limited 
budgets. Finally, Phase III and IV studies incorporate thousands of patients during the cost-
benefit analysis evaluation of the medication relative to placebo (Klein, 1991). These trials 
typically recruit samples too large to feasibly administer comprehensive neuropsychological 
assessments on all patients due to budgetary constraints. 
Because most psychopharmacological studies are designed to assess only positive 
changes in symptoms of depression as a response to medication, the variability in patients’ initial 
experiences of cognitive difficulties (e.g., absence or presence of cognitive problems) can mask 
the mild to moderate effects of the medications. Furthermore, the effects of medications make it 
difficult to measure the full variability of cognitive difficulties endured by patients with 
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depression. Therefore, there has historically been no place in the field of pharmacological studies 
to examine effects of changes to cognition in medicated depressed patients. Furthermore, 
pharmacological researchers have few financial or other incentives to investigate this problem. 
Thus far, neuropsychological studies of healthy adults suggest deleterious cognitive and 
psychological effects from antidepressants with sedative, anticholinergic or histaminic 
components (Amado-Boccara et al., 1992; Hindmarch, 1997). Studies find that tricyclic 
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and 
norepinephrine-reuptake inhibitors (SNRIs) and other antidepressant medications have disparate 
effects on psychomotor speed as measured by reaction time, both between and within medication 
classes. Findings suggest that medications such as nomifensine, bupropion and desipramine 
produce improved psychomotor performance, whereas amitriptyline, dothiepin, and mianserin 
yield significant impairments in reaction time on a driving simulator task (Hindmarch, 1997). On 
the other hand, several antidepressants of varying types have been found to have no effect on 
cognitive performance in healthy control participants (e.g., cericlamine, fluvoxamine, bupropion, 
viloxazine, fluoxetine, and moclobemide). Lastly, a small group of antidepressants appear to 
have a positive effect on cognitive performance in healthy participants (e.g., nomifensine, 
midalcipran, zimeldine, lofepramine, paroxetine, sertraline; Amado-Boccara et al., 1992). These 
incongruent findings suggest that specific medications both within and between antidepressant 
classes may partially explain changes in neuropsychological functioning. It is important to 
consider, however, that because studies such as these include only healthy adults, the evaluation 
of cognitive functioning post medication use may be different for individuals with depression, as 
they have putatively much different brain chemistry.  
Studies examining antidepressant effects in patients with MDD find that several specific 
7 
 
areas of neuropsychological functioning may improve during symptom reduction, including 
verbal declarative memory, for example (Gallagher et al., 2007). Contrastingly, other researchers 
propose that impairments in selective executive functions and working memory remain stable 
after clinical remission (Paelecke-Habermann, Pohl J & Leplow, 2005; Trichard et al., 1995). 
Others suggest that varied antidepressant medications with different neurotransmitter targets may 
have unique cognitive profiles of improvement indicators. For example, Levkovitz et al. (2002) 
proposed that SSRIs may be responsible for more improvements than TCAs in the memory and 
attention functioning of patients with depression. The study found that 6-week administration of 
fluoxetine yielded significant improvement in affective depressive symptoms, attention and 
verbal and visuospatial memory functioning when compared to baseline. Although psychological 
symptomatology also improved with a 6-week administration of desipramine, functioning in the 
domains of memory and attention were not examined (Levkovitz et al., 2002). Thus, continued 
research examining effects of antidepressant medications on specific cognitive domains of 
functioning is still needed. 
Studying Antidepressant Medication in Healthy Adults and Depressed Patients 
Although some research examines the effect of antidepressants on cognitive functioning 
of healthy adults (e.g., Fairweather et al., 1996; Siepmann et al., 2001), the application of this 
method to the real world use of psychotropic medications is relatively flawed. Antidepressants 
are meant to alter brain chemistry in patients experiencing symptomatology. In particular, the 
mechanism of action for SSRIs is, as its name suggests, to selectively block the reuptake of 
serotonin in the synapse. The mechanisms of TCAs work similar to the SSRIs but target blocking 
the reuptake of norepinephrine. A third group of antidepressant drugs acts generally on 
noradrenergic and serotoninergic neurons to enhance the synaptic transmission (Lenox & Frazer, 
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2002). Of special importance, some evidence indicates that antidepressants have different effects 
depending upon severity of depressive symptoms (Fournier et al., 2010; DeRubeis et al., 2012; 
Kirsch et al., 2008): Among patients with mild and moderate symptoms, benefits are negligible 
or nonexistent, whereas among patients with severe symptoms the benefits may be large. 
Similarly, given that brain chemistry is assumed to differ even more substantially between 
healthy adults and patients with MDD, medication intended to remediate neurochemical 
deficiencies in MDD may have different effects among patients than those demonstrated among 
healthy controls in pharmaceutical safety tests. Thus, it is possible that side effect profiles based 
on healthy adults may not generalize to depressed adults, especially those most likely to benefit 
from psychotropic treatment; adverse response to antidepressant medication experienced by 
healthy adults may result because the medications were not intended for their use.  
If antidepressants truly improve brain functioning for areas involved in emotion 
processing and regulation in major depression, they may not have deleterious effects for patients 
(Amado-Boccara et al., 1992). Alternatively, patients with depression who do experience adverse 
cognitive and physical side effects from antidepressant medications may consider those 
worthwhile costs when compared to the broadly debilitating effects of depressive symptoms. For 
instance, Amin et al. (1980) found marked improvement in memory and attention but decrements 
in psychomotor functioning after a 4-week (75-225 mg) daily administration of imipramine to 
depressed patients. These improvements may be considered more beneficial than the adverse 
effects on functioning. 
 A small set of studies has attempted to address the effects of depression alone on 
cognition by evaluating unmedicated patients with MDD, using a design in which assessments 
were conducted within a week of medication initiation (i.e., Ravnkilde et al., 2002; Gohier et al., 
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2009). Authors of these studies argue that effects of the antidepressants are not likely to be 
present within this first week. Therefore, these studies label patients as “unmedicated” and 
compare them to healthy participants and patients with depression who have been 
psychotropically medicated for longer periods of time. This method is problematic, however, as 
the first week of medication is often the time in which most side effects occur, and side effect 
onsets vary by medication (Tollefson, 1991; Stassen et al., 1993). Furthermore, initial onset of 
antidepressant-related symptom-reduction has been examined within one week of onset, as 
opposed to the traditionally viewed changes occurring at 6-8 weeks (Stahl, Nierenberg, & 
Gorman, 2001; Taylor et al., 2006). These side effects and unpredictable onset of medication 
effects may interfere with valid testing and result in different cognitive outcomes relative to the 
actual long term effects of medication compared to those that might be associated with initial 
side effects, placebo responding, and treatment response.  
Studies Examining MDD With and Without Medication and its Effect on Cognition 
Several problems undermine the extant literature of the effects of medication and 
depression, alone and together, on cognitive functioning. The effects of MDD on cognition and 
the effects of MDD plus antidepressant medications on cognition are essentially separate 
questions. Unfortunately, most studies are too underpowered to compare medicated and 
unmedicated groups. Small sample sizes and variability in medication type, dose, duration and 
compliance would make most of these studies weak tests of the hypothesis. These studies 
therefore combine groups of medicated and unmedicated patients with MDD together to enhance 
statistical power in comparisons to healthy adult participants. 
Studies relevant to the cognitive effects of antidepressant medications include at least one 
group of depressed patients (i.e., medicated, or medicated and unmedicated) and a healthy 
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comparison group. Additionally, useable studies of this class must have specified whether 
depressed patients were medicated or unmedicated at the time of testing. Studies examining 
cognitive domains with only antidepressant-medicated patients are not of interest to this topic, 
because it is not possible to disentangle the effects of depression from those of medication.  
Cognitive domains of interest in prior research for medicated and unmedicated patients 
span a broad range of areas including psychomotor and processing speed, attention, 
concentration, inhibition, working memory, and verbal and visuospatial memory. Most studies 
evaluated performance in more than one cognitive domain, which allows for the comparison of 
medication effects across various cognitive domains both within and between samples. The 
patterns reported in these studies have been helpful to compare to the present study. 
Pertinence and Grading Relevance of Studies to the Research Question 
The focus of the present study was to evaluate the unique effects of antidepressant 
medication on cognition apart from the effects of depression on cognition. As such, studies 
including all three groups (unmedicated MDD, medicated MDD and a healthy comparison 
group) for several cognitive domains are most pertinent to address this question. Unfortunately, 
there are surprisingly few studies that include all three groups in a well-characterized fashion that 
evaluate cognitive functioning and depression. In the absence of three-group comparisons, 
studies that include unmedicated MDD patients and those including recently medicated patients 
with MDD are used to infer the most comprehensive understanding of the literature. See Table 2 
for study details and classification outlines. 
Grade A Studies: Direct Evaluation of Medication Effects on Cognition in Depressed Subjects 
In order to examine the usefulness and methodological strengths or weaknesses of past 
studies, the relevant literature is categorized and graded. Grade-A studies are of the highest 
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pertinence and the most methodologically sound to contribute to answering the research 
question. These studies separately compare patients with unmedicated MDD, medicated MDD 
and healthy comparison groups on cognitive domains of functioning.  
Grade B Studies: Direct Evaluation of Depression and Medication Effects in Cognition in 
Depressed Subjects 
Also relevant are Grade-B studies, which include a medicated MDD group compared to a 
healthy comparison group or a recently-medicated MDD group compared to a healthy 
comparison group. Though these studies offer some insights, many are problematic in classifying 
patients with recent medication onset as “unmedicated” in their analyses, as patients may begin 
to show side effects, intended effects of medications within the first week, including also placebo 
effects.  
Grade C Studies: Indirect Evidence of the Effects of Medication or Depression on Cognition in 
Depressed Subjects 
Grade-C studies are those that did not include ideal groups, but offered information about 
the effects of depression or psychotropic medication on cognitive domains of functioning. For 
instance, Grade-C studies included either only unmedicated patients (e.g., Bulmash et al., 2006; 
Grant et al., 2001; Porter et al., 2003) or participants tested pre-SSRI initiation and post-SSRI 
adherence (e.g., Wadsworth et al., 2005), among other methodologies. 
Aims and Hypotheses: 
Aim 1: Examine psychomotor and processing speed among patients with MDD on antidepressant 
medication compared to unmedicated patients and a healthy comparison group.  
 Rather consistent in the literature is the understanding that depressed patients experience 
robust deficits in psychomotor speed. Although few studies examine psychomotor speed using 
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direct cognitive measures from neuropsychological testing, several studies use observational 
measures, self-report measures of psychomotor retardation and agitation, and applied methods 
that parallel daily activities such as gait and driving simulation (Schrijvers, Hulstijn, & Sabbe, 
2008). These studies evaluate both short-term and long-term effects of antidepressants. Although 
direct comparisons of gait and driving simulation tasks are not traditional neuropsychological 
measures, inferences can be drawn based on the improvements experienced by patients with 
depression in these areas. Several studies have found that patients taking medication experience 
improved gait performance (Bader et al., 1999; Lecrubier, 2006) and self-reported psychomotor 
improvements (Ferguson, 2002; Gattaz et al., 1995; Guelfi et al., 2001; Sechter et al., 1999; Stahl 
et al., 2002; Tollefson et al., 1996; Wheatley et al., 1998). Findings suggest that unmedicated 
depressed patients have slower reaction time relative to the healthy comparison group on 
computer tasks as well as in vivo driving manipulation, accuracy and speed tasks (Pier, Hulstijn, 
& Sabbe, 2004).  
 Limited findings from neuropsychological testing suggest that patients with MDD 
successfully treated with antidepressants perform better than untreated patients on the computer 
measures of psychomotor speed (Raoux et al., 1994; Sobin & Sackeim, 1997); however, 
measures such as Digit Symbol and Cancellation yield inconsistent results (Gorenstein et al., 
2006, Ravindran et al., 1995). Findings to date on paper-and-pencil measures of psychomotor 
speed generally suggest that medicated depressed patients and healthy comparison participants 
outperform unmedicated depressed patients (Gualtieri et al., 2006; Raoux et al., 1994; Sobin & 
Sackeim, 1997; Tsourtos et al., 2002; Caligiuri & Ellwanger, 2000). Studies report few 
significant psychomotor deficits in depressed medicated patients (Austin et al., 1992, 1999). 
Because of the limited literature reports of motor deficits in medicated patients, it is difficult to 
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determine whether the psychomotor problems occurred prior to medication onset thereby 
suggesting successful response to antidepressants, or whether the patients are maintaining their 
previously functioning motor abilities.  
Hypothesis 1: With findings indicating a small effect size for psychomotor speed based on 
medication status, it was not clear what to expect in the current study. It was predicted that 
antidepressants would positively influence psychomotor speed, such that healthy comparison 
participants and MDD patients taking antidepressants would outperform unmedicated MDD 
patients. It was also expected that there would be limited differences between medicated 
depressed patients and healthy comparison participants.  
Aim 2: Examine attention and concentration among patients with MDD on antidepressant 
medication compared to unmedicated patients and a healthy comparison group.  
Mixed and null findings in the domains of attention and concentration may partly reflect 
wide differences across studies in the measures used to assess these domains. For example, 
paper-and-pencil measures of attention have yielded minimal to no differences between patients 
with MDD and healthy comparison (Grant et al., 2001); however, studies employing more 
precise and sensitive computerized tasks tend to report such differences more frequently and in 
greater magnitude (Langenecker et al., 2007a; Porter et al., 2003). Specifically, in the areas of 
concentration and inhibitory control, unmedicated MDD patients make more errors of omission 
and commission than do healthy adults on continuous performance computer tasks (Langenecker 
et al., 2007a; Porter et al., 2003). A group of predominantly medicated patients also performed 
more poorly during computer tasks assessing attention and concentration than did the healthy 
comparison group (Langenecker et al., 2007b; Gualtieri et al., 2006). Unmedicated MDD 
patients also have poorer performance than healthy adults and medicated MDD patients on 
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inhibitory control measures (e.g., lure rejections) in computer tasks of sustained attention 
(Langenecker et al., 2005; Porter et al., 2003).  
Hypothesis 2: Given prior findings suggesting superior performance in healthy adults compared 
to medicated and unmedicated depressed patients on sensitive measures of attention, 
concentration and inhibitory control, it was expected that medicated and unmedicated patients 
would perform significantly more poorly than the healthy comparison on measures of inhibitory 
control, with limited differences between the two depressed groups. Similarly, it was expected 
that the healthy comparison adults would outperform medicated and unmedicated MDD patients 
on computer measures of attention and concentration. Few studies have examined the 
performance of medicated depressed patients during paper-and-pencil measures of attention. 
Because it appears that psychotropically medicated and unmedicated patients do not significantly 
differ from each other overall in computer measures of attention and concentration, a similar 
pattern is expected for examiner-administered, non-computerized tasks. Here, both MDD groups 
were expected to underperform relative to the healthy comparison group.  
Aim 3: Examine auditory and visuospatial learning and memory among patients with MDD on 
antidepressant medication compared to unmedicated patients and a healthy comparison group. 
Findings regarding verbal list-learning performance are relatively inconsistent, with a 
number of studies suggesting that patients with MDD have equivalent performance to healthy 
adults in verbal list-learning tasks (Porter et al., 2003; Grant et al., 2001), and others suggesting 
poorer performance on immediate, short-delay free-recall and long-delay free-recall (Considine 
et al., 2011). Furthermore, studies suggest that MDD patients on SSRIs still have more difficulty 
in recalling words during semantic/story learning tasks than non-depressed adults (Ravnkilde et 
al., 2002; Vythilingham et al., 2004). Lastly, evidence suggests that verbal memory differs for 
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old and young depressed adults when compared to nondepressed adults. Specifically, young 
depressed adults exhibit poorer verbal memory than their similar aged healthy peers, despite 
intact processing speed, attention and executive functioning (Hermens et al., 2010).  
The literature suggests that deficits in visuospatial memory functioning are associated 
with unmedicated depression. Some studies report that unmedicated patients with MDD perform 
significantly worse than nondepressed adults in recalling patterns on spatial and recognition tasks  
and for delayed trials on tasks requiring simultaneous matching and delayed matching to sample 
stimuli (Porter et al., 2003). Although few studies examine visuospatial memory among 
psychotropically medicated depressed patients, findings suggest no significant differences 
between unmedicated and medicated patients with depression on visuospatial memory tests. Both 
depressed groups have poorer performance on visuospatial memory and recall than healthy 
adults (Gualtieri, 2006; Langenecker et al., 2005).  
Hypothesis 3: With inconsistent findings regarding verbal memory, significant differences in 
performance on verbal learning memory tasks between medicated patients and healthy 
comparison were not expected. Although little evidence exists, the limited research on 
antidepressants lead to the expectation of significantly stronger performance in healthy adults 
compared to unmedicated patients on verbal memory tasks. Regarding visuospatial memory, it 
was expected that differences between medicated and unmedicated depressed groups would not 
be significant; however, medicated and unmedicated patients would perform more poorly than 
would healthy the healthy comparison group. 
Aim 4: Examine working memory among patients with MDD on antidepressant medication 
compared to unmedicated patients with MDD and a healthy comparison group.  
Unmedicated patients with MDD perform significantly more poorly on tasks of working 
16 
 
memory in visual and verbal domains compared to the healthy comparison participants (Den 
Hartog, 2003; Gohier, 2009; Porter et al., 2003; Ravnikilde et al., 2002). The limited studies 
examining medication status indicate that both medicated and unmedicated depressed groups had 
difficulty in some tasks of set-shifting and working memory (e.g., Tower of London), but did not 
differ from each other (Purcell et al., 1997).  
Hypothesis 4: It was expected that both medicated and unmedicated patients with MDD would 
perform significantly worse than the healthy comparison adults measures of working memory.  
Aim 5: Examine executive functioning among patients with MDD on antidepressant medication 
compared to unmedicated patients and healthy comparison participants. 
Studies of the influence of depression on executive functioning have yielded some mixed 
findings. This inconsistency may be because researchers have interpreted the construct 
differently, thus including different measurements. The literature, however, suggests that 
executive abilities such as planning, organizing, set-shifting and cognitive flexibility appear 
disturbed in patients with depression when compared to healthy adults (Grant et al., 2001, Porter 
et al., 2003; Wadsworth et al., 2005). Few studies have investigated differences in executive 
functioning between stable medicated and unmedicated MDD patient groups in comparison to 
the healthy comparison. Although evidence suggests that patients taking psychotropic 
medications will experience improvements in cognitive functioning as a whole, the limited 
research suggests that medicated and unmedicated patients maintain poorer performance than 
healthy adults on set-shifting tasks, but maintain similar planning abilities as one another (Purcell 
et al., 1997).  
Hypothesis 5: This domain includes tests in which decision-making, planning, and organization 
are the key features of measures, such as performance on the Wisconsin Card Sort test (Grant & 
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Berg, 1948). Given prior findings, it was expected that patients with MDD would show worse 
executive functioning than healthy adults, with unmedicated patients showing the poorest 
functioning and patients on psychotropic medications demonstrating performance intermediate 
between the two other groups. 
Aim 6: Conduct exploratory and illustrative analyses to examine differences between statistical 
methodologies to address empirically and/or theoretically meaningful relationships between age 
and education on neuropsychological function in depression.  
Age and education have shown meaningful theoretical and empirical relationships to 
neuropsychological function; for example, these robust relationships are easily observed in 
normative data used to interpret the tests (e.g., Heaton, Grant, & Matthews, 1986; Heaton et al., 
2003). Moreover, both of these demographic characteristics have been identified as having 
important theoretical and empirical relationships to neuropsychological function in studies of 
depression (e.g., Baune et al., 2012; Lam et al., 2013; Morimoto et al., 2012; Wight et al., 2002). 
A small body of research suggests that depression may have a disproportionate adverse effect 
with advancing age and low education (Andel, 2007; Compton, 2000; Wight et al., 2002). This 
issue is especially relevant to studies of depression and medication effects in depression; for 
example, age is likely confounded with years of illness and years on antidepressant medication, 
in addition to its robust relationship with general cognitive function. Similarly, given links 
between education and access to mental healthcare and utilization of mental health services, 
education is commonly confounded with treatment status and years of treatment. Thus, it is 
important to assess, if not account for, age and education in studies of neuropsychological 
function in depression. 
Problems of systematically confounded variables are frequently observed in 
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observational research like the present study (Miller & Chapman, 2001). Experimental design 
relies on random assignment to groups; only with random assignment can a comparison group 
legitimately be labeled a “control group” (Tabachnick & Fidell, 2007; Guo & Fraser, 2010). In 
contrast, research on naturally occurring clinical phenomena, by its nature, often reflects 
selection bias and shows systematic differences in core characteristics that themselves could 
explain observed group differences. This problem of a systematic confounding variable is 
particularly grave when the group difference favors the hypothesis, and the characteristic that is 
systematically confounded with group status can itself explain the group difference. For instance, 
if a specific condition, such as depression, is hypothesized to have adverse effects on cognition 
as compared to another group, and the group with depression is also systematically older than its 
comparison group, it is not possible to compare the two groups directly. Because statistical 
attempts to remove or control for systematic confounding variables are viewed by some as 
difficult if not impossible (See Miller & Chapman, 2001 for review), the presence of such a 
confound is often considered a fatal flaw in a study. Efforts to understand and deal with this 
problem would therefore be very beneficial. 
Hypothesis 6: As the present study was the first to compare various methods of accounting for 
highly related variables systematically confounded with neuropsychological performance in a 
depressed sample, empirically-based hypotheses were difficult to form. However, a conceptual 
understanding of each method offers insights from which theoretical hypotheses were created. 
Each method assessed the same phenomena, which provided the expectation that the pattern of 
results should be similar across the methods; however, different methods yield a range of effect 
sizes for depression status and antidepressant medications on neuropsychological function 
related to differences in the rigor, sensitivities, and technical aspects of the methods. 
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The primary goal of this aim was to compare and discuss the conceptual underpinnings of 
different statistical methods used to account for systematic covariates, so that a chosen 
methodology would be consistent with theoretical and logical assumptions required by it. 
Overall, it was expected that the methods would identify a relatively similar pattern of findings 
(e.g., domains identified). However, the sensitivity to identify specific measures that yield 
significant results may differ by methodology.  The ability to compare and contrast these 
measures can offer some greater depth of understanding of sensitivity and strengths and 
weaknesses for a given approach. 
Summary and Purpose 
In all, the lack of research within the fields of pharmacology and neuropsychology 
examining the effects of antidepressant medications in depressed patients on specific cognitive 
domains such as attention, concentration, inhibition, executive functioning, psychomotor speed, 
working memory, and verbal and visuospatial memory inhibits our ability to inform patients 
comprehensively in their decisions to take antidepressant medications, or at the least provide 
cost-benefit tradeoffs. Accordingly, the current study investigated decrements and improvements 
in these areas of cognitive functioning among three groups: unmedicated patients with MDD, 
patients with MDD who were currently taking antidepressant medications for treatment of their 
symptoms, and nondepressed healthy adults. The main goal of the present study was to provide 
practitioners and consumers with new and useful information about the effects of antidepressant 
medications on cognitive functioning. This study also aimed to provide researchers with 
information to make informed decisions about the appropriate methodologies to use in 
accounting for covariates that are highly related to dependent variables but not the central point 
of interest. 
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CHAPTER 2 
METHOD 
Participants 
Participants included 331 adults (117 men, 214 women): 178 adults with Major 
Depressive Disorder (89 taking antidepressant medications and 89 unmedicated) and 153 
nondepressed healthy adults from research records of internal and externally funded protocols. 
Tables 3 and 4 present demographic information for the sample and depressed groups, 
respectively. As seen in Table 3, the participants ranged in age from 18 and 88 years old and 
ranged in education from 7 to 23 years. Table 4 indicates that, among participants with MDD, 
age of onset ranged from 3.0 – 60.0 years (M = 41.9, SD = 19.1). Severity of depressive 
symptoms as assessed by self-report on the Beck Depression Inventory-II (Beck et al., 1961) 
ranged from 0 - 50; the average endorsement (M = 23.8, SD = 12.9) corresponded to moderate 
depression. Clinician-rated severity of depressive symptoms as assessed by the Hamilton 
Depression Rating Scale (Hamilton, 1967) ranged from 0 to 41; the average endorsement (M = 
15.6, SD = 8.0) also corresponded to the moderate depression range.  
This was an archival study that combined deidentified records of multiple protocols, each 
of which was conducted and approved according to institutional review board (IRB) guidelines. 
Appendix B provides a copy of the Wayne State University IRB approval of the present study. 
Recruitment of MDD participants occurred through the University of Michigan Depression 
Center, University of Michigan Turner Geriatric Center, the Michigan Clinical Outcomes and 
Research Engines (MStrides) program, University of Michigan Clinical Studies (UM Engage), as 
well as community advertisement; recruitment of healthy comparison participants occurred 
through advertisements in the community and MStrides and UM Engage. Exclusionary criteria 
included contraindications for MRI, as the funded research project included an imaging 
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component; presence or history of psychotic symptoms, bipolar disorder, dementia, head injury, 
schizophrenia; history of ECT, or other medical conditions that are likely to affect cognition 
(e.g., epilepsy). 
Measures 
Determination of MDD status and psychiatric screening. All participants were 
administered the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) to screen 
out for history of psychiatric illness in the healthy comparison group and to confirm MDD status 
in depressed participants (First, Spitzer, & Gibbon, 1995). Depression severity was measured 
with the Hamilton Rating Scale for Depression–Second Edition (HDRS; Hamilton, 1967), Beck 
Depression Inventory–II (Beck, 1961) and SCID-I severity measures (First, Spitzer, & Gibbon, 
1995).  
Neuropsychological Tests. All eligible participants were administered a comprehensive 
battery of neuropsychological measures.  
Controlled Oral Word Association Test (Benton, Sivan, Hamsher, Varney, & Spreen, 
1994). The Controlled Oral Word Association Test (COWAT) is a word-list generation task that 
requires participants to produce as many words as possible beginning with a given letter of the 
within 1-minute trials (e.g., letters C, F, and L). COWA forms CFL and PRW were used, as they 
have been found to be equivalent in difficulty (Mitrushina, Boone, and D’Elia, 1999). The 
current study evaluates total valid words generated for the three trials. Successful completion of 
the COWAT requires phonemic fluency and cognitive initiation.  
California Verbal Learning Test – 2nd Edition (CVLT-II; Delis, Kramer, Kaplan, & 
Ober, 2000). The CVLT-II is a verbal list-learning task in which examinees are required to learn 
a list of 16 words presented verbally over five consecutive trials (List A). The words comprise 
22 
 
four semantic categories, read in a standardized, uncategorized order. Following the fifth trial of 
List A, participants are presented with a 16-item distracter list to recall immediately (List B). The 
participant is then asked to recall the original list of words without prompt Free (short-delay free 
recall, SDFR) and category-cued (short-delay cued recall, SDCR) trials of List A follow the 
immediate free recall of List B. After a 30-minute delay, List A is again assessed with free recall 
(long-delay free recall, LDFR) trials. Lastly, a forced-choice recognition trial contains the 16 
target items from List A and 32 distracter items. During the recognition trial, the examiner orally 
presents each of the 48 items and the examinee indicates whether or not the item was included in 
List A. The current study examines Trial 1 words, which parallels digits forward as an index of 
simple attention; total words recalled over the five learning trials of List A, as an index of global 
learning, and LDFR as an index of verbal memory. 
Trail Making Tests (Reitan & Wolfson, 1985). The Trail Making Test, parts A and B 
(TMT-A and TMT-B), is a two-part, timed, paper-and pencil measure with numeric and alpha-
numeric sequencing tasks. In TMT-A, participants are instructed to connect circled numbers 
from 1 to 25 in numerical sequence as quickly and accurately as possible (i.e., 1-2-3). TMT-B 
requires participants to connect circled numbers and letters in sequence alternating between 
numbers and letters from 1 to 13 (i.e., 1-A-2-B-3-C). Successful completion of these tasks 
requires visual searching, psychomotor speed and agility, and attention. Successful completion of 
TMT-B also requires the ability to shift cognitive set, indicating cognitive flexibility (Spreen & 
Strauss, 1998). desRosiers and Kavanaugh (1987) developed alternate forms (TMT-C and TMT-
D). Alternate-form reliability coefficients between TMT-A and TMT-C were .66 to .79, and .88 
to .89 for TMT-B and TMT-D. The present study examines total time in seconds to complete 
each part of the test.  
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Wisconsin Card Sort Test (Berg, 1948; Heaton et al., 1993). The Wisconsin Card Sort 
Test (WCST) requires novel problem-solving, and the abilities to shift and maintain cognitive 
set. Participants categorize 128 cards by visual characteristics of four key cards (i.e., color, form, 
and number). The examiner gives feedback to the participant as to whether the card was matched 
correctly to the standardized characteristic after each card is placed (e.g., “correct” or 
“incorrect”). The characteristic by which participants are to match the cards changes throughout 
the task. Successful completion of the WCST requires ability to shift cognitive sets and respond 
to examiner feedback in order to decipher the changing categorical rule. The current study 
evaluates perseverative errors.  
Digit Span (Wechsler, 1997). The Wechsler Memory Scales- 3rd Edition, Digit Span 
(WMS-III, Digit Span) task is a two-part verbal measure of attention and working memory. In 
the first trial, Digits Forward, participants repeat number series of increasing length (beginning 
with two numbers, maximum nine numbers), immediately following the oral presentation of the 
series by the examiner. Digits Forward is widely used as an index of simple attention. In the 
second trial, Digits Backward, participants are directed to repeat numerical strings aloud in 
reverse order. This task involves both working memory and sequential processing. The present 
study examined total digits recalled for the forward trial and total digits recalled for the 
backward trial. 
Purdue Pegboard (Tiffin, 1948). The Purdue Pegboard is a widely used timed test that 
measures visual-motor coordination via gross movement of arms, hands, and fingers in addition 
to fingertip dexterity. Trials assess differences in dominant and non-dominant hands, as well as 
bilateral coordinated movements. In the dominant and nondominant trials, participants use one 
hand to pick up one peg at a time and place it into the holes quickly as possible within 30 
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seconds, without skipping any holes. In the third trial, the participant completes the same process 
using both hands. Examinees must place the pegs into the holes simultaneously to receive credit 
for each peg. The three phases (dominant hand, nondominant hand, and both hands) may be 
repeated to calculate an average performance over several trials. The current study evaluates the 
total pegs placed on the dominant-hand.  
Michigan Spatial Relation Test (Langenecker et al., 2005). The Michigan Spatial 
Relation Test (MSRT-10/35) assesses visual learning and memory. The task is an extension of 
the 7/24 Spatial Recall Test (Rao, Hammeke, & McQuillan, 1984) to a 10/35 on a 5 x 7 grid 
(Pattern A) in 10-second intervals. After each presentation participants are asked to reproduce 
the pattern by placing tokens onto a blank grid. Five learning trials are assessed with immediate 
recall. Following the fifth trial is a single interference trial that presents a distracter pattern for 10 
seconds with assessment of immediate recall (Pattern B). The participant must then recall the 
original design without reviewing the stimulus (short-delay free recall). Long-delay free recall 
(MSRT-LDFR) is assessed following 20 - minute delay. Lastly, is a copy trial, in which the 
examinee is asked to reproduce the original design using a model. The current study will 
evaluate the global spatial learning score, as reflected in total correct over Trials 1 – 5 (MSRT-
Total) and the long-delay free recall (MSRT-LDFR), an index of visuospatial memory. 
Parametric Go/No-Go Task (Langenecker et al., 2005). The Parametric Go/No-Go 
(PGNG) Task is a computer-administered test of sustained, selective, and divided attention and 
inhibitory control. Participants are presented with a string of letters. In the “Go” task, examinees 
are directed to respond only to a prescribed set of target letters (e.g., x, y, and z) and not respond 
to all other stimuli. In the “No-Go” version, participants are directed to respond to one of three 
target letters only if they had just responded to either of the other two target letters. This task 
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requires participants to track the last target to which they responded and inhibit responding to a 
target letter on successive presentations. Successful completion of the “Go” portion of the test 
requires sustained attention and set maintenance through percent correct target trials for all three 
levels. The present study will evaluate participants’ ability to complete the “No-Go” task 
requirements of cognitive flexibility by examining set-shifting, complex processing speed, and 
inhibitory control. Set-shifting will be measured through percent correct target trials on level 2 
(Go Accuracy). Complex processing speed will be measured through based on response time 
skills exercised in level 1 (Go Reaction Time). Inhibitory control will be measured through 
percent correct on inhibitory trials for levels 2 and 3 (No-Go Accuracy). 
Procedure 
Participants completed informed consent procedures per Institutional Review Board 
guidelines. Potential participants were contacted by research assistants via phone and screened 
briefly for basic inclusion criteria. If phone-screening criteria were met, individuals were 
scheduled for in-person screening, in which they were administered a series of psychological and 
health screening measures by research assistants and psychologists. After completing the clinical 
interview, eligible participants were administered a battery of neuropsychological measures 
including paper-and-pencil and computer testing. Participants were paid for participation. 
Statistical Analyses 
Data for all test indices were converted to a common metric (z score), unadjusted for 
demographic characteristics, using normative expectations as specified in the test manuals. Tests 
with scoring rubrics that utilized demographic adjustments were set for all participants to 
correspond to reference group normative expectations (i.e., adult men age 25-44 years, with 12 
years of education). In this manner, the effects of demographics can be assessed independently, 
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the indices can be directly compared, and a neuropsychological composite score reflecting 
overall functioning can be calculated using the mean z scores of the individual indices. Table 3 
presents the indices for each test linked to the cognitive domains. 
Descriptive statistics were conducted for the overall sample and diagnostic groups 
separately. Neuropsychological test data were examined by domain, using individual and domain 
composite measures, with a series of analysis of variance (ANOVA) followed by simple 
contrasts.  
As age and education are often highly related to neuropsychological performance in 
general (Heaton, Grant, & Matthews, 1986; Heaton et al., 2003), and for patients with depression 
(e.g., Baune et al., 2012; Lam et al., 2013; Morimoto et al., 2012; Wight et al., 2002), the current 
study conducted exploratory analyses using several available statistical methods to address the 
relationship between age and education and neuropsychological functioning among unmedicated 
participants with MDD (uMDD), medicated participants with MDD (mMDD), and healthy 
comparison (HC) groups. These methods included: analysis of covariance (ANCOVA), matched-
sample analysis, regression-residual method, and propensity scores analyses (PSA). A brief 
review of practical information about each method is presented next. 
Analysis of Covariance Method. Analysis of Covariance (ANCOVA) is a direct 
extension of ANOVA, in which main effects and interactions of a model are assessed after the 
dependent variable has been adjusted in light of its relationship with covariates. Although it is 
often used to “control” for group differences on variables considered extraneous or nuisance in a 
research design, Miller and Chapman (2001) describe that the ANCOVA method was developed 
to increase power to test an independent variable by reducing within-group variance: When 
covariate(s) account for unexplained variance in a model, the error term is reduced. The core 
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assumptions of ANCOVA cited throughout the literature include conditional normality, 
homoscedasticity, independence of observations, linearity of regression, covariates are perfectly 
reliable and with homogeneous slopes, and equivalent covariate values between or among groups 
(Tabachnick & Fidell, 2007; Fleiss & Tanur, 1973). Thus, ANCOVA is an appropriate method 
when a covariate is related to the outcome but is randomly distributed across the group (i.e., the 
groups are equivalent on the covariate). Although controversial due to the frequent violation of 
its core assumptions (Fleiss & Tanur, 1973; Lord, 1967), ANCOVA is commonly used to 
address systematic confounds. The current study conducted the ANCOVA method for illustrative 
purposes to allow for the comparison of ANCOVA results with other methodologies used to 
manage systematic covariates. 
Matched-samples Method. Presented with a design in which controlling or accounting 
for a characteristic is desired, many researchers opt to match their groups on such 
characteristic(s). There are several methods to match groups, including univariate matching and 
varied multivariate matching techniques. In any case, participants from separate groups are 
matched on the variable that is believed to be correlated with the dependent variable (Kirk, 
2012). It is important to note that formal matched-samples method is not the same as “equivalent 
samples;” the latter simply means that the group differences on the characteristics are not 
statistically significant, which can reflect a combination of power associated with sample size 
and the magnitude of the difference. Depending on the research question of interest, researchers 
may employ one of several matching strategies; some of these techniques include nearest 
available metric matching, caliper matching, minimum distance metric matching, minimum 
distance circular matching, or discriminant matching (Cochran & Rubin, 1973). The most 
commonly used of these methods is minimum distance metric matching, in which participants 
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from separate groups are matched on all confounding variables according to a fixed rule; this is 
the matching method used for the current study, in which participants were paired to individuals 
in a comparison group using matching rules for age (+ 5 years) and education (+ 3 years).  
 Regression-residuals “Regression Line” Method. The Regression-residual method fits 
a regression line between the covariate(s) and the dependent variable using a criterion group 
(e.g., healthy comparison; Fleiss & Tanur, 1973). Predicted scores for other groups are generated 
using the formula weights from the criterion group; the predicted scores are then compared to 
actual scores to produce residuals. These residuals represent the effect of the dependent variable 
beyond that attributable to the effect of the covariate observed among the criterion sample (e.g., 
the differences on a neuropsychological index in excess of that due to age and education). Group 
contrasts (e.g., ANOVA or t test) can be conducted to examine the residuals. 
 Propensity Score Analysis Method. Propensity Score Analysis (PSA) estimates the 
probability that each participant is assigned to all groups by equating groups on identified 
covariates (Guo & Fraser, 2010). As such, PSA can be used to correct for selection bias in 
observational studies. Data were evaluated in pairwise contrasts using the Nearest Neighbor 
Matching for Average Treatment Effects (nnmatch). Nnmatch estimates the average treatment 
effect on the dependent variables of interest by matching cases in the treatment group to the 
healthy comparison group based on covariates of interest. A unique feature of this method is that 
individual observations in the healthy comparison group can be used as a match more than once 
in a single matching analysis (i.e., “matching with replacement;” Abadie et al., 2004). Another 
unique and desirable feature of nnmatch is that it allows for use of more than one match per case 
(i.e., “oversampling”). Thus, a single case in the treatment group could be matched to multiple 
nearest neighbor healthy comparison participants. Researchers can identify the number of 
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matches to be made per observation; the current study specified four matches, as recommended 
by Guo and Fraser (2010). The Mahalanobis metric was used as the weighting matrix to specify 
the relative weight to place on each variable in defining the nearest neighbor match. Essentially, 
the Mahalanobis metric assesses the distance between data points. The bias-corrected estimator 
was chosen for a regression-adjustment using the original matching variables, which adjusts the 
matches for the differences on the covariate using least squares on the matched observations 
(Abadie et al., 2004). A robust variance estimator was selected to allow for heteroscedasticity. 
The average treatment effect (ATE) was chosen to determine the average treatment effect for the 
population rather than the average treatment effect for the treated (ATT) group. Unlike the ATT 
that is estimated by averaging the within-pair differences to evaluate whether the treatment was 
beneficial for those who received the intervention, the ATE, examines for treatment effects by 
comparing groups who did and did not receive the treatment. This matching procedure creates a 
counterfactual outcome (i.e., a simulation of what would be the case if the matched conditions 
were true) to evaluate the overall effectiveness of the treatment implemented. Lastly, to 
maximize generalizability, the analyses specified estimation of the population variance rather 
than the sample variance.  
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CHAPTER 3 
RESULTS 
Descriptive statistics for demographic characteristics and neuropsychological tests 
descriptive statistics are presented in Table 3 for the three groups: unmedicated participants with 
MDD (uMDD), medicated participants with MDD (mMDD), and healthy comparison (HC). To 
facilitate comparisons across indices, all neuropsychological tests are reported in Z scores. The 
three groups differed on age, F(2, 328) = 6.04, p = .003; participants in the mMDD group were 
older than participants in the HC and uMDD groups, which did not differ. Education was not 
significantly different among the groups, F(2,328) = 0.43, p = .651. 
Descriptive statistics for depression-related characteristics are presented in Table 4 for 
unmedicated and medicated depressed groups, including percentages of the mMDD group taking 
antidepressants from each medication class. Groups were equivalent for age of onset, t(116) = 
0.58, p = .563. The effectiveness of antidepressants on depressive symptoms was assessed via 
the BDI-II and HDRS. Using the interpretive guidelines recommended by the test author (Beck, 
1996), on average, both groups reported moderately severe symptoms of depression on the BDI-
II. Similarly, using cutpoints recommended for the HDRS (Hamilton, 1960), clinicians rated both 
groups as having moderately severe depression. However, the uMDD group showed greater 
depression severity than did the mMDD group, on both the self-reported BDI-II, t(163) = 3.68, p 
< .001, Cohen’s d = 0.61, and the clinician-rated HDRS, t(167) = 4.00, p < .001, Cohen’s d = 
0.57.  
Group Contrasts Using Analysis of Variance 
Analyses of Variance (ANOVA) were conducted to compare the three groups on all 
neuropsychological indices and cognitive domain composite scores. As seen in Table 6, the 
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ANOVAs indicated that performance among the groups was significantly different for measures 
of processing speed, attention, and some aspects of the learning and memory domain. However, 
the groups were generally equivalent on measures of working memory and executive functioning 
domains.  
Post hoc analyses using simple contrasts indicated that the significant effects in 
processing speed abilities were driven by worse performance of the mMDD group as compared 
to the HC and uMDD groups. Effect sizes were interpreted according to guidelines presented by 
Cohen (1988), in which d = 0.20 reflects a small effect, d =0.50 reflects a medium effect, and d 
> 0.80 is large. As shown in Table 6, differences in the processing speed abilities revealed 
generally medium effect sizes (d = .32 – .57, median = .43) for mMDD participants compared to 
HC and uMDD groups. The most pronounced difference within the processing speed domain 
was seen in the uMDD and mMDD contrast effect size for Purdue Pegboard. The HC and uMDD 
groups were statistically equivalent in performance on all processing speed indices. 
Post hoc analyses for the domain of attention revealed a similar pattern of significant 
effects driven by poorer performance of the mMDD group compared to HC and uMDD, with 
generally small to medium effect sizes (d = 0.28 – 0.51, median = 0.41). The most notable 
differences in attention abilities were seen in the uMDD and mMDD contrast. Lastly, significant 
differences were observed for the learning-memory composite and the verbal learning measure. 
Post hoc analyses for these measures of learning and memory again indicated significant effects 
driven by worse performance of the mMDD group compared to HC and uMDD groups. 
Differences in performance yielded small to medium effect sizes (d = 0.25 – 0.56, median = 
0.36), with the most pronounced difference seen in the uMDD and mMDD contrast for the 
learning and memory composite. The HC and uMDD groups were equivalent in performance on 
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all attention and learning-memory indices. 
Group Contrasts Accounting for Age and Education 
ANOVAs provided the most common perspective of the effects of depression and 
medication status on neuropsychological performance; however, the groups differed significantly 
on age, with an older mMDD group than both the HC and uMDD groups. Furthermore, 
consistent with most samples, age was significantly correlated with the vast majority of cognitive 
performance measures, thereby identifying it as a confounding variable to group differences in 
neuropsychological performance (Table 7). The relationship between age and cognitive 
performance was especially high for psychomotor functioning, and verbal and visual learning 
and memory. In other words, it is possible that the group differences observed on the ANOVAs 
were driven, at least in part, by age and not group membership. Education was not significantly 
different across the groups and showed few significant correlations to neuropsychological 
performance in the total sample, but it showed small and significant correlations with a variety of 
the indices across the three separate groups. 
For demonstrative and educational purposes, the following sections provide results from 
various methods used to address covariate analyses for age and education in group comparisons 
on the neuropsychological indices, organized from the most to least commonly used methods in 
the current literature: analysis of covariance (ANCOVA), matched-sample analysis, regression-
residual method, and propensity scores. Consideration of advantages, disadvantages, and 
appropriateness of each method will be comprehensively addressed in the discussion. The eager 
reader may wish to skip to Table 12, which compares results from each statistical methodology. 
 Analysis of Covariance (ANCOVA). The use of ANCOVA would not normally be 
recommended for the present study due to the violation of core ANCOVA assumptions; 
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specifically, the independent variable, group membership, was related to the covariate of age, as 
the medicated patients with depression were significantly older than the other two groups.  
However, ANCOVA analyses were conducted on each of the neuropsychological indices using 
age and education as covariates for illustrative purposes. As shown in Table 8, the ANCOVA 
results are similar to those observed from unadjusted ANOVA, with significant differences seen 
in performance for processing speed and attention measures. Effect sizes were attenuated due to 
accounting for contributing effects of age and education. Differences in processing speed 
revealed medium effect sizes (d = 0.31 – 0.41) for mMDD compared to HC and uMDD groups. 
The largest effect size within the processing speed domain was seen in the HC and mMDD 
contrast. Post hoc analyses for attention revealed a similar pattern of significant effects driven by 
weaker performance of the mMDD group compared to HC and uMDD groups. Effect sizes were 
moderate (d = 0.32 – 0.44), with the most pronounced difference in attention abilities seen in the 
uMDD and mMDD contrast on Digit Span Forward. Due to the attenuation of group differences 
after accounting for age and education in ANCOVA, differences in learning and memory 
performance that were observed in the unadjusted ANOVAs were no longer significant. The 
groups remained equivalent on indices of working memory and executive functions, similar to 
the results of the ANOVA. 
Matched-samples Analyses. Table 9a depicts the descriptive statistics for the Matched-
samples groups on demographic characteristics and neuropsychological test performance 
measures. As expected, the sample size became smaller than for the alternative methods due to 
tailoring of groups to match participants according to the age and education rules. Despite the 
decrease in power associated with reduced sample size, the pattern of results was largely 
consistent with those observed for ANCOVA, with significant differences revealed in measures 
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of processing speed and attention, and statistically equivalent performances observed across the 
groups for working memory and executive functioning measures (Table 9b). With the exception 
of the Learning-Memory Composite, measures within the domain of learning and memory were 
equivalent across groups. Effect sizes from the Matched-samples t test analyses were attenuated 
as compared to ANOVA for the Learning-Memory Composite and a measure of attention (Digit 
Span Forward), but were strengthened for the Processing Speed Composite and Purdue Pegboard 
measure. Significant differences on the Processing Speed Composite revealed a medium effect 
size (d = 0.55), reflecting inferior performance of mMDD compared to HC. Small to medium 
effect sizes (d = 0.44 – 0.62) for mMDD compared to HC and uMDD groups were present on the 
Purdue Pegboard task. Although still yielding significantly different performance, t tests revealed 
attenuated effects on Digit Span Forward (d = .48) and Learning-Memory Composite (d = 0.39) 
from ANOVA, driven by weaker performance of the mMDD group compared to uMDD group 
and HC group, respectively.  
Regression-residual Method. The Regression-residual method employed in the present 
study used the HC group as the criterion model of the relationship of the covariates age and 
education to the neuropsychological performance indices. Residual scores were generated for the 
uMDD and mMDD groups using the formula weights from the HC group to yield predicted 
scores that were then subtracted from actual scores (Fleiss & Tanur, 1973). Results for the 
Regression-residuals method are reported in Table 10, and revealed a similar pattern of findings 
to the Matched-samples methodology, with attenuated effect sizes compared to ANOVA results. 
The Regression-residual results had relatively equivalent effect sizes compared to ANCOVA and 
Matched-samples methodologies. Analyses also revealed equivalent performance across groups 
on measures of working memory and executive functions, and significant differences between 
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the groups on tasks of processing speed and attention, similar to results of the ANCOVA and 
Matched-samples methodologies. Regression-residual analyses yielded varied performance on 
learning and memory tasks.  
Specifically, differences in the processing speed abilities were driven by worse 
performance for the mMDD group compared to HC and mMDD groups, with small effect sizes 
(d = 0.30 – 0.39). The most pronounced difference within the processing speed domain was seen 
in the HC and mMDD contrast for the Processing Speed Composite. Post hoc analyses within the 
attention domain revealed a similar pattern of significant effects driven by weaker performance 
of the mMDD group compared to HC and uMDD. Effect sizes were moderate (d = .34 – .39), 
with the most pronounced difference in attention abilities again seen in the uMDD and mMDD 
contrast on Digit Span Forward, with weaker mMDD performance. Lastly, the differences in 
performance on the Learning-Memory Composite was also driven by underperformance of 
mMDD participants compared to HC and uMDD, with small effect sizes (d = 0.34 – 0.35). 
Propensity Score Method. Data for the Propensity Score method were evaluated in 
pairwise contrasts using the Nearest Neighbor Matching (nnmatch) for Average Treatment 
Effects (ATE). Results of the Propensity Score Matching Estimator analyses are presented in 
Table 11. Similar to previous methods, results from PSA showed significant differences in 
performance for uMDD compared to mMDD on processing speed and attention, and for HC 
versus mMDD for the Processing Speed Composite. Results for the learning and memory 
domain revealed significant differences in performance for the HC versus mMDD and uMDD 
versus mMDD groups on the Learning-Memory Composite. All groups had equivalent 
performances for working memory and executive functioning domains.  
Differences in group performance on processing speed abilities were again indicative of 
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worse performance for the mMDD group compared to HC and uMDD groups, with effect sizes 
ranging from d = 0.34 – 0.35; the most prominent difference within the processing speed domain 
was for the Processing Speed Composite. The simple contrasts on measures of attention also 
showed worse performance of mMDD compared to HC and uMDD groups. Effect sizes varied 
from small to medium (d = 0.22 – 0.58), with the most pronounced difference in attention 
abilities again seen between the uMDD and mMDD groups on Digit Span Forward.  
Summary of Group Comparisons 
In sum, all the analyses yielded significant differences between HC versus mMDD 
groups and uMDD versus mMDD groups for processing speed and attention domains with 
medium effect sizes; analyses also revealed similar patterns for the learning and memory 
domain, but only for the composite score. All methods yielded statistically equivalent 
performances among the groups for working memory and executive functioning. The HC and 
uMDD groups performed equivalently for all domains regardless of the analysis type (Table 12).  
In comparing the methods of covariate adjustment, the pattern of significant results 
across the methods used to account for age and education indicates that the ANOVA method 
liberally identified group differences and produced larger effect sizes compared to all age- and 
education- adjusted methods. The PSA and Matched-samples analyses typically produced the 
most conservative results in terms of frequency in yielding statistically significant differences. 
With regard to effect sizes, the adjustment methods yielded generally similar results; 
however, examination of patterns across all results (independent of significance level) revealed a 
reduction in effect size for methods that accounted for age and education compared to the 
ANOVA results. The most notably attenuated effects, compared to unadjusted ANOVAs, were 
observed in the PSA method for the HC versus uMDD and HC versus mMDD contrasts and 
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Matched-samples method for the uMDD versus mMDD contrast. For results with significant 
group differences, the various methods were generally consistent in their pattern and range of 
effect sizes, with methods that accounted for covariates finding small to medium effects (d = 
0.22 – 0.62). For HC-mMDD in processing speed, unadjusted d (i.e., ANOVA) = 0.5, whereas 
the average d across the methods adjusting for age and education was 0.4; for attention, 
unadjusted d = 0.4, and average adjusted d = 0.3; for learning-memory, unadjusted d = 0.5, 
average adjusted d = 0.4. For uMDD-mMDD comparisons in processing speed, unadjusted d = -
0.4 (i.e., uMDD outperforming mMDD), whereas the average d across the methods adjusting for 
age and education was -0.2; for attention, unadjusted d = -0.5, and average adjusted d = -0.3; for 
learning-memory, unadjusted d = -0.6, average adjusted d = -0.4.  
Occasions in which results diverged by method were also examined. Disparate results 
from the overall consensus of significant results occurred under a number of conditions: the 
Matched-samples method identified fewer significant differences than the other methods (likely 
due to reduced sample size or an idiosyncratic sampling of selected participants), the PSA 
method identified fewer significant group differences for the HC versus mMDD contrast, and all 
age- and education- adjusted methods identified fewer group differences compared to ANOVAs.  
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CHAPTER 4 
DISCUSSION 
The present study found that adults with MDD who were taking antidepressant 
medications generally performed more poorly on tasks of processing speed, attention, and the 
learning and memory composite compared to unmedicated adults with MDD and nondepressed 
healthy adults. This finding suggests that, although treatment with antidepressants was associated 
with substantial amelioration of affective symptoms of depression, patients on the medications 
may experience adverse cognitive complications distinct from depression. In fact, despite 
experiencing moderate to severe depressive symptoms, patients with MDD not taking 
antidepressant medications performed similarly to nondepressed healthy adults in several 
domains of neuropsychological functioning. Interestingly, the cognitive processes most disrupted 
by antidepressant medication included lower-level, fundamental processes. These findings 
diverge from prior studies, which identified differences in higher-order functioning (e.g., 
working memory, executive functioning, etc.) between healthy and depressed adults (Purcell et 
al., 1997; Gualtieri et al., 2006).   
Although the literature has long demonstrated the need to consider age and education 
when examining neuropsychological performance in healthy and neurologically impaired adults 
(Heaton, Grant, & Matthews, 1986; & Heaton et al., 2003), the current study highlights the 
relevance of this issue when examining patients with depression. The importance of considering 
these characteristics is evident by the divergent findings from the unadjusted (i.e., simple 
ANOVA) versus age- and education- adjusted methods of comparing patients with and without 
MDD. The present study also highlights the importance of choosing the appropriate 
methodology with which to adjust for covariates, as the methods vary in the magnitude of 
effects, methodological strengths and weaknesses, and theoretical rationale. Lastly, and perhaps 
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of the utmost importance, is the current study’s review of the appropriateness of using statistical 
methods to make adjustments and “control” for covariates; improperly using any of the 
“adjustment” methods when statistical assumptions are violated can misrepresent findings, often 
more liberally to the benefit of the research question.  
Cognitive Impairment Associated with Depression and Antidepressant Medications 
Conclusions regarding processing speed and attention performance are noteworthy, as 
findings from the present study are inconsistent with those of prior studies. Prior studies on 
processing speed indicate equivalent performance between medicated patients with MDD and 
healthy adults, with relative deficits in performance observed among unmedicated patients with 
MDD (Tsourtos et al., 2002; Gualtieri et al., 2006). However, limited findings suggest that MDD 
patients who are taking antidepressants may have psychomotor difficulties starting within the 
first month of antidepressant use (Amin et al., 1980). The literature on attention performance has 
reported superior ability among healthy adults as compared to patients with MDD, and 
equivalent performance among patients with MDD regardless of medication status (Gualtieri et 
al., 2006). The present study, however, found that individuals with MDD taking antidepressants 
performed worse than unmedicated patients and healthy adults in processing speed and attention, 
with equivalent performance between the latter two groups. One explanation for the 
incompatible findings with those of prior studies could be due to the varied effects of different 
antidepressant classes, as previous research indicates that decrements in psychomotor 
functioning occur more among patients with MDD taking TCAs than among those taking SSRIs 
(Elliot, 1998; Wadsworth et al., 2005). However, antidepressant subtype does not likely drive 
group differences in the present study because fewer than 6% of participants taking medications 
included TCA or MAOIs in the regimen; the vast majority were prescribed SSRI and SNRI 
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medications individually or in combination. Another possibility is that medications other than 
antidepressants prescribed for these participants were different in kind, quantity, or in combined 
effects for participants taking antidepressants as compared to those who were not. Patients 
requiring combinations of medication may be more intractable to treatment, and it would be 
difficult to tease apart the effects of multiple drugs and the psychiatric disturbance. Lastly, it is 
possible that the prior studies with which these findings clash were limited and flawed; they are 
few in number and reported on small samples of patients with depression (Tsourtos et al., 2002; 
Gualtieri et al., 2006).  
Findings regarding the effects of MDD status and antidepressant status on verbal and 
visual learning and memory were varied. The diverse outcomes depended on the measure, 
modality (i.e., visual or verbal) and analysis method employed. Inconsistency of findings 
observed in the present study within the learning and memory domain appear to parallel the 
variations seen in the existing literature. In general, the understanding of learning and memory 
functioning from the limited research available suggests that healthy adults and unmedicated 
adults with MDD individuals perform equivalently (Gaultieri et al., 2005), with some studies 
suggesting poorer performance among medicated adults with MDD compared to healthy adults 
(Hermens et al., 2010; Sweeney et al., 2000). Findings did not support the hypothesis predicting 
stronger learning and memory performance in healthy adults and adults with MDD on 
antidepressants compared to unmedicated adults with MDD; in the present study, the medicated 
MDD group performed worse than did the unmedicated MDD and healthy comparison groups on 
verbal learning. In contrast to the hypothesis, equivalent performances were observed across the 
three groups on all other indices of learning and memory. 
The findings for the cognitive domains of working memory and executive functioning 
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were also inconsistent with the hypotheses. Although these predictions were made from the 
insubstantial literature available on the topic, previous studies suggested that individuals with 
MDD would underperform compared to healthy adults on tasks of visual working memory 
(Purcell et al., 1997; Porter et al., 2003) and set-shifting components of executive functioning 
(Grant et al., 2001; Porter et al., 2003) and perform equivalently for executive functioning tasks 
of planning, verbal fluency, and cognitive flexibility (Purcell et al., 1997; Gualtieri et al., 2006; 
Porter et al., 2003) and verbal working memory (Gorenstein et al., 2006). However, both MDD 
groups in the present study performed equivalent to healthy adults on all indices of working 
memory and executive functioning. In addition to the potential explanations discussed for 
findings on the other cognitive domains, the contrasting findings in the literature and present 
study may result from the use of different measures to examine working memory and executive 
functioning domains, as these constructs are fairly complex and often interpreted differently by 
research teams. 
Comparing Methods to Account for Group Differences on a Covariate: Strengths, 
Weaknesses, and Appropriate Uses of Adjustment Methodologies 
This section will explore the strengths, weakness, and important aspects to consider when 
choosing a method to address systematic covariates.  
Analysis of Covariance to Account for Group Differences on a Covariate. Analysis of 
covariance (ANCOVA) is an appropriate method when a covariate is related to the outcome but 
is randomly distributed across group (i.e., the groups are equivalent on the covariate). The 
ANCOVA approach offers the advantage of reducing error variance in models associated with 
extraneous characteristics when evaluating the relationship of group status to the dependent 
variable (Miller & Chapman, 2001 for review). However, researchers often fail to ensure that all 
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core assumptions of ANCOVA are met before proceeding with the analyses. Ironically, violation 
of the criterion that groups are equivalent on the covariate values between or among groups is 
frequently the reason that researchers adopt ANCOVA: Very often in observational research 
designs, groups differ on an important characteristic that is related to the outcome and could 
itself drive group differences on the outcome. Researchers wanting to “account” for the group 
difference on the characteristic use ANCOVA; however, this is not a valid use of ANCOVA 
because the covariate is not independent or distributed independently with respect to the 
treatment effect (see Miller & Chapman, 2001 for review). For instance, one cannot statistically 
remove the effect of anxiety from depression if the two phenomena are overlapping constructs 
because to do so would yield a distorted remnant of the construct of depression, much like 
removing all water from soup would yield a dehydrated remnant that lacks the essential character 
of soup (Miller & Chapman, 2001). In the same way, removing age or education from 
depression-medication status in the current study may obstruct illuminating information about 
characteristics of the groups by inadvertently removing their unique features. Lastly, the 
ANCOVA method is viewed in the technical literature as inappropriate unless the groups were 
determined by random assignment (Miller & Chapman, 2001). 
 Matched Sample to Account for Group Differences on a Covariate. The Matched-
samples method works to directly address differences on an independent variable that are related 
to the outcome between groups. Although effective in eliminating significant differences on the 
covariate, the Matched-samples method often works at the cost of losing power associated with a 
reduced sample size, because not all participants will be matched. As demonstrated in the current 
study, the loss of sample size and power can be considerable and is idiosyncratic to the specific 
sample. Another drawback to the Matched-samples method is that it can be labor intensive to 
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identify the optimal set of cases that maximizes sample size, while keeping the magnitude of 
difference on the matched variable ecologically valid (i.e., not exceeding a meaningful difference 
on the characteristic). A third disadvantage of using the Matched-samples method is that the 
nature of the participants included in the sample may limit the ecological validity because many 
of the differences on the neutralized (matched) variable exist as part of the phenomenon. For 
example, in the present sample age of MDD onset is understandably related to current age, but it 
is also related to years of illness and treatment; thus, adjusting for age also removes effects 
associated with years of illness and years taking antidepressant medications, which might have 
cumulative adverse effects on cognition. Therefore, we have no way of knowing the extent to 
which deletions of unpaired cases made during the matching process may selectively limit the 
generalizability of the findings from the chosen portion of the sample.   
Matching participants at the point of recruitment might be a better alternative, provided 
that no person from the smallest group to be recruited is turned away. The unmedicated and 
medicated depressed groups tend to be smaller and more difficulty to recruit than the healthy 
comparison group in depression research. Therefore, healthy adult participants would be 
selectively matched to the MDD groups at the point of recruitment to ensure a tight match 
between groups.  As the present study was a pooling of many small studies, where cognitive 
testing was not the primary dependent variable, and medication status was not the primary 
recruitment criterion for MDD participants, having disproportionate ages in the mMDD groups 
could not be matched apriori. 
Regression-residuals Method to Account for Group Differences on a Covariate. 
Regression-residual analysis is an appropriate method for analyses when between-group 
comparisons are required (Miller & Chapman, 2001). This method allows for direct comparison 
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of performance for several groups to the criterion group. According to Fleiss and Tanur (1973), 
Regression-residual analyses are ideally conducted when the criterion group is a random sample 
of the population of interest. Yet, most non-experimental, observational research does not have 
this luxury. Researchers have therefore established that Regression-residual analyses can be used 
appropriately if the criterion group has sufficient variability in the mean responses  (Fleiss & 
Tanur, 1973). Another weakness to the Regression-residual method is that it may have a 
procedural artifact that the makes the method more vulnerable to random error. By definition, the 
criterion group is a perfect fit to the line and all other groups deviate from it. Random error in the 
fit of the criterion-group regression line can therefore produce false or exaggerated differences in 
the fit of the regression line for predicted results made for other groups (Miller & Chapman, 
2001).  In addition, non-linearity in the regression line may result in skewed variances from the 
regression line, resulting in an overly conservative estimate process. 
 Propensity Score Analysis to Account for Group Differences on a Covariate. The 
Propensity Score Analysis (PSA) is a method that is gaining momentum in the field of 
psychology, as it can handle heteroscedasticity and allows researchers to balance data when 
treatment assignment and imbedded demographic characteristics of treatment groups cannot be 
ignored in nonrandomized studies (Guo & Fraser, 2010). The matching estimators PSA can also 
be used to estimate treatment effects of samples and populations, as it can examine treatment 
effects of the treated group and/or compare groups on the effects of an intervention in the treated 
group to a group that did not receive the treatment. Another benefit of PSA, and the Nearest 
Neighbor (Nnmatch) procedure specifically, is that it includes the option to match with 
replacement, which allows individual values in the criterion group to serve as a match multiple 
times in a single matching analysis. When treatment and comparison groups differ greatly, 
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multiple-match comparison seems particularly advantageous. This option typically reduces bias 
because the average quality of the match improves; on the other hand, it increases variance in the 
estimator as compared to methods employing matching without replacement because it reduces 
the number of excluded cases used to create the counterfactual outcome (Smith & Todd, 2005).  
Like any methodology, PSA has its disadvantages as well: For one, the quality of 
matching continuous covariates in PSA is limited by the quality of the available criterion group. 
Secondly, although PSA has the capability to examine the quality of match, the process is 
extensive and requires further expertise. The limited exposure of PSA in the fields of psychology 
and neuropsychology also makes findings of PSA difficult to communicate quickly and 
effectively.  
Comparing Methods of Adjusting for Covariates. This study provides a sample of 
comparisons for the methodologies. In terms of significance tests, the PSA and matched-samples 
methods tended to yield the most conservative outcomes; this is an expected pattern with the 
matched-samples method due to diminished power from reduced sample size, but it likely 
reflects a stable characteristic of the PSA method. Because PSA sampled four cases as 
comparisons to each treatment case, the method is inherently less reactive to idiosyncratic 
characteristics of individual case matches and enhances stability of estimates. PSA is essentially 
a multidimensional and dynamic extension of the matched-samples method. Matched-samples 
method using minimum distance metric matching is effectively a unidimensional version of 
PSA, with the drawbacks of using one only match per case and consequently lowering power due 
to unmatched cases. As such, it would be more prone to random error than PSA.  
In terms of effect size estimates, across a single performance index the effect sizes for the 
different statistical methods showed marked range, sometimes varying nearly half a standard 
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deviation; for example, the comparison of medicated MDD with healthy adults on learning-
memory composite ranged from an inconsequential effect using PSA (d = .14) to a medium-large 
effect using matched-sample (d = .62). Over the entire set of comparisons, however, the average 
effects yielded by the methods were generally very similar. The matched-sample method was the 
most idiosyncratic, after ANOVA, tallying the most estimates as the largest effect and also the 
most estimates as the smallest effect. PSA tended to yield relatively conservative estimates 
overall but also did so in a narrower range as compared to the other methods, and it did not yield 
the smallest estimates most frequently.  
Misusing ANCOVA is still wrong. Of note, the observation that ANCOVA yielded 
generally similar results to those observed by the other methods does not obviate the fact that the 
technique is theoretically incorrect under these circumstances (i.e., a covariate confounded with 
group status).  In this instance, sample size was large, variance was equivalent in age, and mean 
and variance were equivalent in education.  Were there to be more notable covariance 
differences across groups, one could expect ANCOVA to perform less well, and with more error.  
Further, with a smaller sample size and less statistical power than present in the current study, 
the methods may have yielded more a divergent than consistent pattern of findings. The 
difference in age between the healthy comparison adults and medicated patients with MDD was 
d = .33, slightly smaller than the effect of the healthy comparison group compared to the 
medicated patients with MDD on processing speed and attention composites.  With smaller 
sample sizes, and larger age differences, the ANCOVA method cannot actually result in an 
overly conservative result.   
Limitations and Future Research 
Despite addressing difficult, yet real, issues in conducting research of neuropsychological 
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performance in depressed groups, the present study had several limitations. Firstly, the current 
study was observational and was restricted by its non-randomization to groups.  The participants 
in the medicated depressed group likely represent more severely depressed individuals who were 
previously less responsive to treatment than the unmedicated group of individuals, which may 
reflect a real and meaningful sampling bias.  Secondly, because the data were archival and 
compiled from several research projects, detailed medication information for all participants 
(e.g., dosage, recent changes in medication, time of day medication was taken relative to the 
evaluation, years on the medication, other medications in the regimen, etc.) was not collected and 
therefore could not be empirically considered as a possible influence on performance. 
Furthermore, participants were not recruited on the basis of antidepressant use or antidepressant 
class, therefore making it challenging to attain sufficient power to examine effects of medication 
class on performance. Another limitation of the present study was the high level of education of 
the sample, with a limited range of education. The participants also had good access to mental 
healthcare and were screened out for a recent history of substance abuse and dependence, which 
may not be representative of the general community of patients with depression. These 
characteristics potentially limit the generalizability of the findings. Lastly, because this was an 
illustrative study, numerous kinds of analyses were conducted to evaluate how to manage 
systematic confounds best, which inflates the probability of Type I error. It is important to note, 
however, that the pattern of findings across adjusted analyses was generally consistent.  
Future research should examine the effects of antidepressant medication on cognition 
separate from the effects of depressive prospectively, as many of the limitations (e.g., collecting 
medication information) can be addressed during the recruitment and data collection process. 
Studies should include participants with MDD who represent a broad range of demographic 
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characteristics (e.g., education, race, etc.). In addition to recruiting participants with similar age 
and education, researchers may benefit from matching depressed groups by depression severity 
and years of medication treatment (although this may limit the sample size) to allow for a cleaner 
evaluation of the research question.  
Conclusions 
The findings of this study provide some initial support that antidepressant medications 
affect several areas of cognition, including processing speed, attention, and some areas of 
learning and memory. With regard to domain-specific hypotheses, the findings are generally not 
consistent with the existing literature. This deviance may be due to sample-specific 
characteristics (e.g., highly educated participants, length and types of treatment, selection biases 
inherent in medication status, etc.), as well as the small samples included in previous research 
studies on the topic. The present study also offers convincing evidence for the importance of 
appropriately attending to age and education, as it relates to neuropsychological functioning 
among individuals with major depressive disorder.  
The present study is one of few in the literature to evaluate differences in cognitive 
functioning associated with depression status and medication status separately and 
simultaneously, comparing unmedicated adults with MDD to those taking antidepressant 
medications and to nondepressed healthy adults. The general literature on effectiveness of 
antidepressant medications suggests that medicated patients experience benefit in treatment for 
reduction of symptoms; however, a growing literature indicates that individuals with different 
subtypes and severity of depression have substantially different profiles of responsiveness to 
medication (Kirsch et al., 2008). It will be important to continue examining the importance of 
depression severity and depression subtypes on cognitive functioning. Findings indicate that, 
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although patients with MDD who take antidepressant medications experience improvement in 
their emotional symptoms, the side effects of such medications may yield adverse effects on 
attention and processing speed. It is important to pursue research on the ecological cost-benefit 
tradeoff of antidepressants in terms of the positive effects on mood and the detrimental effects on 
cognition. Furthermore, it is important for practitioners to communicate potential adverse 
cognitive effects, as they may disrupt job functioning and potentially increase risk in complex 
psychomotor activities such as driving. It may be the case that slowed processing speed is a bona 
fide reason to see educational and occupational accommodations, such as extra time to meet task 
requirements and deadlines. The present study highlights that antidepressant treatment is not 
without meaningful adverse consequence and therefore should not be overused or prescribed by 
default without careful consideration by providers and consumers. 
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APPENDIX A 
Table 1. Comparative findings of unmedicated patients with Major Depressive Disorder (uMDD) 
and Healthy Comparison (HC) participants organized by cognitive domain  
Domain Author Year 
uMDD 
(N) 
HC 
(N) Effects of Interest 
Psychomotor Functioning 
 
Bulshman et al. 2006 18 29 HC > uMDD RT and number of crashes 
on driving simulation  
 
Porter et al. 2003 44 44 HC = uMDD DSST 
 
Grant et al.  2001 123 36 HC = uMDD TMT-A, CPT verbal and 
visual discriminative ability  
 
Gualtieri et al.  2006 38 69 HC = uMDD finger-tapping;  
HC > MDD CPT RT, DSST  
Attention, Inhibition, and Concentration 
 
Porter et al. 2003 44 44 HC = uMDD verbal fluency;  
HC > uMDD VCPT commission and 
omission errors 
 Langenecker et al. 2007 20 22 HC > uMDD RT on CPT 
 
Grant et al.  2001 123 36 HC = uMDD TMT-A, DS, and CPT 
 Gualtieri et al. 2006 38 69 HC > uMDD complex attention 
Learning and Memory (Verbal and Visuospatial) 
 
Porter et al.  2003 44 44 HC = uMDD RAVLT 
HC > uMDD RAVLT distractor list 
 
Gualtieri et al. 2006 38 69 HC = uMDD VBM area 
Working Memory 
 
Den Hartog et al. 2003 30 38 HC = uMDD MST-2, verbal fluency 
HC > uMDD MST-1 
 
Porter et al. 2003 44 44 HC > uMDD SWM errors  
 
Grant et al. 2001 123 36 HC > uMDD CANTAB SWM  
Executive Functioning 
 
Porter et al. 2003 44 44 HC > uMDD COWAT 
 
Grant et al. 2001 123 36 HC = uMDD TMT-B, category and 
verbal fluency;  
HC > MDD WCST 
 
Den Hartog et al. 2003 30 38 HC > uMDD Stroop 
Note. X > Y = Group X performed better on the task than Group Y. uMDD = unmedicated 
MDD; HC = healthy comparison; COWAT= Controlled Oral Word Association Task; TMT-A/B 
= Trail Making Test-Part A/B; WCST = Wisconsin Card Sorting Task, VCPT = Vigil 
Continuous Performance Test; RT = Reaction Time; CPT = Continuous Performance Task; DS = 
Digit Span; DSST: Digit Symbol Substitution Task; MST = Memory Scanning Test; CANTAB = 
Cambridge Neuopsychological Test Automated Battery; SWM = Spatial Working Memory; 
RAVLT = Rey Auditory Verbal Learning Test
Table 2. Studies organized by relevance to current study and cognitive domain 
Author (Year) Sample 
Psychomotor 
Processing Speed 
Attention, Inhibition, 
Concentration 
Learning- 
Memory   
Working  
Memory Executive Functioning 
Grade A       
Purcell et al. 
(1997) 
20 HC 
8 uMDD 
12 mMDD 
   HC > MDD  ToL HC = MDD planning 
task, ToL 
Tsourtos et al. 
(2002) 
20 HC  
20 uMDD 
19 mMDD 
mMDD > uMDD, 
HC > uMDD, HC = 
mMDD  RT 
computer task  
    
Gualtieri et al. 
(2006) 
 
 
 
 
69 HC 
38 uMDD 
31 mMDD 
HC = MDD  finger 
tapping; HC > 
uMDD RT CPT, DS 
HC > MDD  CPT; 
HC > uMDD  
complex attention; 
mMDD > uMDD 
complex attention, 
vigilance 
H = MDD  visual/ 
verbal memory; HC 
= uMDD  VBM 
area 
 HC > MDD  Stroop 
errors, shifting 
attention; mMDD > 
uMDD, HC = mMDD 
cognitive flexibility 
Grade B        
Gohier et al. 
(2009)  
20 HC 
20 mMDD 
HC > mMDD  
TMT-A secs 
HC > mMDD on 
Prose Distraction 
Task, TMT-A secs; 
HC = mMDD TMT-
A  errors 
  HC > mMDD   Stroop 
color, HSC (Part 2), 
Modified 6 rule shifts, 
elements test simple 
dual task, TMT-B 
time & errors  
HC = mMDD MCST 
execution, PE & trials 
Hermens et al. 
(2010) 
17 HC 
20mMDD 
  HC > mMDD 
RAVLT 
 HC > mMDD TMT-B  
Sweeney et al. 
(2000) 
51 HC 
58 mMDD 
HC = mMDD 
computer RT tests 
 HC > mMDD 
visual delayed 
HC = mMDD  
SWM 
HC = mMDD  ID/ED 
attentional set-shifting 
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Author (Year) Sample 
Psychomotor 
Processing Speed 
Attention, Inhibition, 
Concentration 
Learning- 
Memory   
Working  
Memory Executive Functioning 
match to sample  
Ravnkilde et al. 
(2002) 
49 HC 
20 mMDD 
20*mMDD 
 
HC > mMDD 
TMT-A secs, DS 
HC > mMDD DSF, 
Subtracting Serial 7s 
49 HC 40 mMDD 
WMS-R VR I & II, 
WMS-R LM I & II, 
LVLT  
HC > mMDD 
DSB  
HC > mMDD  Stroop, 
TMT-B secs, verbal 
fluency, WCST 
Gorenstein et al. 
(2006) 
31 HC 
56 mMDD 
HC = mMDD DS, 
RT, tapping, symbol 
coding, cancellation 
mMDD = HC DSF HC = mMDD = 
verbal recall 
HC = mMDD 
DSB 
 
Grade C       
Wadsworth et 
al. (2005) 
161 
HC/MDD 
17 SSRI 
no detrimental 
effects in SSRI on 
motor speed 
no detrimental 
effects in SSRI on 
speed of focus in 
attention 
SSRI HC < SSRI 
MDD episodic 
memory, recog. 
memory, delayed 
recall;  SSRI  < 
nSSRI episodic 
memory, recog. 
memory, delayed 
recall 
 
 
Porter et al.  
(2003) 
44 HC 
44 uMDD 
HC = uMDD on DS 
Substitution Task 
HC > uMDD VCPT 
omission & 
comission errors,  
HC = uMDD 
RAVLT; HC > 
uMDD  RAVLT 
distract list 
HC > uMDD 
SWM, interaction 
of level 
HC =  uMDD verbal 
fluency, HC > uMDD 
ToL 
 
 
Grant et al.   
(2001) 
36 HC 
123 uMDD 
HC = uMDD  
TMT-A secs, RT, 
discriminative 
ability on 
visual/verbal  CPT 
HC = uMDD on 
TMT-A, DS, CPT 
 HC > uMDD  
CANTAB SWM 
HC = uMDD TMT-B, 
verbal & semantic 
fluency; HC > uMDD 
WCST 
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Author (Year) Sample 
Psychomotor 
Processing Speed 
Attention, Inhibition, 
Concentration 
Learning- 
Memory   
Working  
Memory Executive Functioning 
Den Hartog et 
al. (2003) 
38 HC  
30 uMDD 
HC = uMDD MST-
2 and VFT secs 16–
60; HC > uMDD on 
MST-1 
   HC > uMDD Stroop 
Langenecker  
et al. (2007) 
22 HC 
20 uMDD 
HC > uMDD RT on 
CPT 
   
 
Bulshman et al., 
(2007) 
29 HC 
18 uMDD 
HC > uMDD 
steering RT, driving 
simulation crashes 
    
Meyer et al.  
  (2006)  
21 HC 
21 mMDD 
HC = mMDD finger 
tapping 
    
Naismith et  
  al. (2002) 
20 HC 
47 mDD 
HC > mMDD 
TMT-A & TMT-B 
secs 
    
 Note. uMDD =  unmedicated MDD; mMDD = medicated MDD; MDD = both MDD groups; HC = healthy comparison;    
*mMDD = recently medicated MDD; SSRI = on selective serotonin reuptake inhibitor; nSSRI = not on SSRI; ToL = Tower of 
London; RT = reaction time; DS = Digit Symbol; PE = perseverative errors; HSC = Hayling Sentence Completion; MCST = Modified 
Card Sorting Test; RAVLT = Rey Auditory Verbal Learning Test; ID/ED = Intradimensional/ Extradimensional; SWM = Spatial 
Working Memory; WCST  = Wisconsin Card Sorting Test; DSF = Digit Span Forward; DSB = Digit Span Backward; WMS-R VR = 
Wechsler Memory Scale-Revised Visual Reproduction; WMS-R LM = WMS-R Logical Memory; LVLT = Luria Verbal Learning 
Test ; VCPT = vigil continuous performance tests; TMT = Trail Making Test (Parts A & B); CANTAB = Cambridge 
Neuropsychological Test Automated Battery; MST-1 = memory scanning test; VFT = Verbal Fluency Test
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Table 3. Descriptive Statistics for Demographic Characteristics and Neuropsychological Tests: 
Healthy Comparison, Unmedicated MDD, and Medicated MDD Groups 
 
 HC 
(n = 153) 
uMDD 
(n = 89) 
mMDD 
(n = 89) 
 
Variable M (SD) M (SD) M (SD) Range 
 
Age (years) 40.7 (19.9) 38.2 (16.1) 47. 5 (19.4) 18.0 – 88.0 
Education (years) 15.7 (2.2) 15.5 (2.5) 15.8 (2.5) 7.0 – 23.0 
Percent Women 58.8   61.8   77.5     
 
Psychomotor Speed Composite -0.77 (0.94) -0.87 (0.87) -1.27 (0.99) -4.87 – 1.24 
 Purdue Pegboard -1.81 (1.24) -1.72 (1.02) -2.36 (1.21) -5.39 – 1.51 
 Trails A 0.24 (0.69) 0.18 (0.74) -0.14 (0.91) -2.50 – 1.67 
 Go Reaction Time -0.69 (1.35) -0.90 (1.17) -1.12 (1.34) -5.00 – 1.88 
        
Attention Composite -0.06 (0.75) 0.01 (0.77) -0.41 (0.87) -2.40 – 2.70 
 Digit Span Forward -0.74 (0.65) 0.58 (0.68) -0.91 (0.56) -1.89 – 1.44 
 CVLT-II Trial 1 0.62 (1.26) 0.55 (1.24) 0.06 (1.20) -2.27 – 4.36 
 Go Accuracy -0.23 (1.05) -0.08 (1.02) -0.28 (1.17) -4.80 – 0.88 
        
Learning-Memory Composite 0.39 (0.82) 0.43 (0.75) -0.04 (0.92) -2.64 – 1.89 
 CVLT-II Total 1-5  0.63 (0.90) 0.57 (0.90) 0.27 (1.14) -2.49 – 2.33 
 CVLT-II Long Delay Free Recall 0.50 (0.83) 0.61 (0.77) 0.27 (1.01) -2.21 – 1.44 
 MSRT Total 1-5 -0.06 (1.01) -0.03 (0.96) -0.32 (1.17) -2.93 – 1.39 
 MSRT Long Delay Free Recall -0.03 (1.04) -0.15 (0.91) -0.20 (1.06) -2.94 – 0.75 
        
Working Memory Composite -0.45 (0.69) 0.43 (0.78) -0.59 (0.71) -2.58 – 1.50 
 Digit Span Backward -1.23 (0.63) -1.21 (0.68) -1.41 (0.48) -2.58 – 0.97 
 No- Go Accuracy  0.18 (0.79) 0.15 (0.88) 0.14 (0.86) -2.20 – 1.50 
        
Executive Functioning Composite 0.01 (0.75) 0.07 (0.63) -0.14 (0.97) -3.88 – 1.18 
 COWAT 0.18 (1.06) 0.31 (0.84) 0.20 (0.93) -2.41 – 2.73  
 Trails B 0.39 (0.60) 0.35 (0.55) 0.17 (0.82) -2.74 – 1.24 
 WCST Perseverative Errors -0.54 (1.52) -0.50 (1.39) -0.90 (2.17) -7.00 – 0.76 
        
 
Note. uMDD = Unmedicated – Major Depressive Disorder group, mMDD = Medicated – Major 
Depressive Disorder group, CVLT = California Verbal Learning Test, MSRT = Michigan Spatial 
Relation Test, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card 
Sorting Test. Tests expressed in Z scores standardized on a reference sample, age 25-44, 
education 12 years. 
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Table 4. Descriptive Statistics for Depression-Related Characteristics for Unmedicated MDD 
(uMDD) and Medicated MDD (mMDD) Groups 
 
 uMDD 
(n = 89) 
mMDD 
(n = 89)  
Variable M (SD) M (SD) Range 
      
MDD Age of Onset (years) 22.8 (16.1) 21. 4 (12.1) 3.0 – 60.0 
      
Depression Symptoms      
Hamilton Depression Rating Scale 17.9 (7.3) 13.1 (8.3) 0.0 – 41.0 
Beck Depression Inventory-II 27.0 (11.3) 19.8 (13.9) 0.0 – 50.0 
      
Medication Classifications1      
SSRI (%)     60.6   
SNRI (%)     43.8   
TCA (%)     3.3   
MAOI (%)     2.2   
Other (%)     3.4   
      
 
Note. SSRI = Selective Serotonin Reuptake Inhibitor, SNRI = Serotonin Norepinephrine 
Reuptake Inhibitor, TCA = Tricyclic antidepressant, MAOI = Monoamine Oxidase Inhibitor. 
1. Percent of participants taking each medication type (including overlap); 56.1% taking 
multiple classes of medications. 
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Table 5. Indices of neuropsychological function organized by cognitive domain. 
Domain Index 
  
Psychomotor speed and dexterity:  
 Purdue Pegboard  Pegs placed, dominant hand 
 Trail-Making Test-Part A  Seconds to complete 
 Parametric Go/No-Go Mean response time (msec) to Go targets (Level 1) 
  
Attention/Concentration:   
 Digit Span Forward Percentile 
 CVLT-II Trial 1 words 
 Parametric Go/No-Go  Go percent correct (Level 1) 
  
Learning and Memory:   
  Auditory  
 CVLT-II Total words Trials 1 – 5 
 CVLT-II Long-delay free recall (CVLT-LDFR) 
  Visuospatial   
 MSRT Total Trials 1 – 5 (MSRT-Total) 
 MSRT  long-delay free recall (MSRT-LDFR) 
  
Working Memory:   
 Digit Span Backward Percentile 
 Parametric Go/No-Go  No-go mean percent correct (Levels 2 – 3) 
 
  
Executive Functioning:  
 COWAT Total words (CFL, PRW) 
 WCST Perseverative errors 
 Trail-Making Test-Part B Seconds to complete 
 
Note. CVLT-II = California Verbal Learning Test–II, LDFR = Long-delay free recall, MSRT = 
Michigan Spatial Relation Test, COWAT = Controlled Oral Word Association Test, WCST = 
Wisconsin Card Sorting Test.  
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Table 6. Unadjusted ANOVA Group Comparisons for Neuropsychological Tests for Healthy 
Comparison, Unmedicated MDD and Medicated MDD Groups. 
 
Variable Mdiff (SEdiff) F or t df p Cohen’s d 
       
Processing Speed Composite   8.27 2, 325 < .001   
HC vs. uMDD 0.10 (0.12) 0.78 237 .437 0.10 
HC vs. mMDD 0.50 (0.13) 3.89 238 .000 0.52 
uMDD vs. mMDD -0.40 (0.14) 2.88 175 .004 -0.43 
 Purdue Pegboard   7.33 2, 296 < .001   
HC vs. uMDD -0.09 (0.16) 0.54 217 .587 -0.08 
HC vs. mMDD 0.55 (0.17) 3.15 212 .002 0.44 
uMDD vs. mMDD -0.64 (0.17) 3.66 163 < .001 -0.57 
 Trails A   5.80 2, 270 .003   
HC vs. uMDD 0.06 (0.10) 0.58 200 .562 0.08 
HC vs. mMDD 0.37 (0.12) 3.27 194 .001 0.48 
uMDD vs. mMDD -0.32 (0.14) 2.34 147 .021 -0.38 
 Go Reaction Time   2.63 2, 282 .074   
HC vs. uMDD 0.20 (0.18) 1.10 209 .272 0.16 
HC vs. mMDD 0.43 (0.20) 2.20 206 .029 0.32 
uMDD vs. mMDD -0.23 (0.21) 1.10 149 .272 -0.18 
Attention Composite   7.54 2, 328 .001  
HC vs. uMDD -0.07 (0.10) -0.68 240 .500 -0.09 
HC vs. mMDD 0.35 (0.11) 3.29 240 .001 0.44 
uMDD vs. mMDD -0.42 (0.12) 3.39 176 .001 -0.51 
 Digit Span Forward    4.87 2, 270 .008   
HC vs. uMDD 0.15 (0.10) -1.58 198 .115 -0.20 
HC vs. mMDD 0.17 (0.09) 1.89 195 .060 0.28 
uMDD vs. mMDD -0.33 (0.10) 3.19 147 .002 -0.44 
 CVLT-II Trial 1   6.12 2, 323 .002   
HC vs. uMDD 0.07 (0.17) 0.39 236 .695 0.05 
HC vs. mMDD 0.56 (0.17) 3.37 236 .001 0.45 
uMDD vs. mMDD -0.50 (0.18) 2.70 174 .008 -0.41 
 Go Accuracy   3.75 2, 282 .025   
HC vs. uMDD -0.15 (0.15) -1.04 209 .301 -0.15 
HC vs. mMDD 0.35 (0.17) 1.98 206 .049 0.29 
uMDD vs. mMDD -0.50 (0.20) 2.46 131.1a .015 -0.40 
Learning-Memory Composite    9.35 2, 326 < .001   
HC vs. uMDD -0.04 (0.11) -0.39 238 .694 -0.05 
HC vs. mMDD 0.43 (0.11) 3.74 239 < .001 0.50 
uMDD vs. mMDD -0.47 (0.13) 3.73 175 < .001 -0.56 
 CVLT-II Total 1-5    4.05 2, 323 .018   
HC vs. uMDD 0.05 (0.12) 0.43 236 .669 0.06 
HC vs. mMDD 0.36 (0.13) 2.70 236 .007 0.36 
uMDD vs. mMDD -0.31 (0.15) 1.99 165.4a .048 -0.30 
(table continues) 
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Variable Mdiff (SEdiff) F or t df p Cohen’s d 
 CVLT-II LDFR    3.41 2, 321 .553  
HC vs. uMDD -0.11 (0.11) -0.96 234 .340 -0.13 
HC vs. mMDD 0.23 (0.12) 1.88 235 .061 0.25 
uMDD vs. mMDD -0.33 (0.14) 2.44 163.7a .016 -0.37 
 MSRT Total 1-5    1.57 2, 221 .211   
HC vs. uMDD -0.03 (0.18) -0.15 147 .882 -0.03 
HC vs. mMDD 0.26 (0.16) 1.56 176 .121 0.24 
uMDD vs. mMDD -0.28 (0.20) 1.38 119 .171 -0.26 
 MSRT LDFR   0.59 2, 220 .553   
HC vs. uMDD -0.11 (0.18) 0.63 147 .528 -0.11 
HC vs. mMDD 0.16 (0.16) 1.03 175 .303 0.16 
uMDD vs. mMDD -0.05 (0.19) 0.28 118 .781 -0.05 
Working Memory Composite   1.05 2, 320 .350   
HC vs. uMDD -0.07 (0.10) 0.73 234 .465 0.10 
HC vs. mMDD 0.14 (0.09) 1.48 235 .140 0.20 
uMDD vs. mMDD -0.07 (0.11) 0.60 171 .552 -0.09 
 Digit Span Backward   0.08 2, 282 .071   
HC vs. uMDD -0.01 (0.09) -0.15 199 .878 -0.02 
HC vs. mMDD 0.19 (0.09) 2.17 195 .031 0.23 
uMDD vs. mMDD -0.20 (0.10) 2.11 137.3a .037 -0.34 
 No-Go Accuracy   0.08 2, 282 .921   
HC vs. uMDD 0.04 (0.12) 0.32 209 .752 0.04 
HC vs. mMDD 0.04 (0.12) 0.36 206 .716 0.05 
uMDD vs. mMDD -0.01 (0.14) 0.04 149 .968 -0.01 
Executive Function Composite   1.42 2, 281 .244   
HC vs. uMDD -0.06 (-0.10) -0.59 208 .555 -0.08 
HC vs. mMDD 0.15 (0.12) 1.21 204 .227 0.18 
uMDD vs. mMDD -0.21 (0.13) 1.57 150 .119 -0.25 
 COWAT    0.48 2, 269 .617   
HC vs. uMDD -0.13 (0.14) -0.95 207 .345 -0.14 
HC vs. mMDD -0.02 (0.16) -0.12 193 .903 -0.02 
uMDD vs. mMDD -0.11 (0.15) 0.77 138 .445 -0.13 
 Trails B   2.81 2, 270 .062   
HC vs. uMDD 0.04 (0.08) 0.53 199 .599 0.08 
HC vs. mMDD 0.23 (0.10) 2.21 194 .028 0.33 
uMDD vs. mMDD -0.18 (0.11) 1.59 147 .114 -0.26 
 WCST Perseverative Errors     2, 245 .325   
HC vs. uMDD -0.04 (0.22) -0.19 190 .853 -0.03 
HC vs. mMDD 0.36 (0.28) 1.27 174 .206 0.20 
uMDD vs. mMDD -0.40 (0.32) 1.21 188.8a .231 -0.23 
Note. CVLT = California Verbal Learning Test, MSRT = Michigan Spatial Relation Test, LDFR 
= Long Delay Free Recall, COWAT = Controlled Oral Word Association Test, WCST = 
Wisconsin Card Sorting Test. Tests expressed in Z scores standardized on a reference sample, 
age 25-44, education 12 years. 
a. Levene’s correction for heterogeneity of variance. 
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Table 7. Descriptive Correlations: Age, Education, Depression Severity, and 
Neuropsychological Performance - All Participants (N = 331) 
 
 Age Education HDRS BDI-II 
1.   Age -- -.10 -.01 .02  
2.   Education  -- -.09 -.07 
3.  Hamilton Depression Rating Scale (HDRS)    --        .89** 
4.  Beck Depression Inventory-II (BDI-II)      -- 
5. Processing Speed Composite -.42** -.05 -.11 -.14* 
6.  Purdue Pegboard -.50** -.03 -.04 -.11 
7.  Trails A -.44** -.06 -.09 -.09 
8. Go Reaction Time -.37** -.10 -.10 -.09 
9. Attention Composite -.43** .05 -.05 -.05 
10.  Digit Span Forward -.14* .01 .02 -.02 
11.  CVLT-II Trial 1 -.39** .05 -.08 -.08 
12. Go Accuracy -.39** .04 -.02 -.03 
13. Learning-Memory Composite -.56** .08 -.09 -.10 
14.  CVLT-II Total 1-5 -.48** .11* -.12* -.12* 
15.  CVLT-II Long Delay Free Recall -.45** .11 -.07 -.08 
16. MSRT Total 1-5 -.52** -.02 -.09 -.07 
17. MSRT Long Delay Free Recall -.50** -.01 -.11 -.09 
18. Working Memory Composite -.13* -.07 -.06 -.05 
19.  Digit Span Backward -.22** -.02 -.01 -.07 
20. No-Go Accuracy -.02 -.06 -.05 .01 
21. Executive Functioning Composite -.44** .03 -.01 -.01 
22.  COWAT -.16** .10 .02 .03 
23.  Trails B -.52** -.08 -.07 -.08 
24. WCST Perseverative Errors -.36** .05 -.02 -.01 
25. Neuropsychological Composite -.51** .07 -.10 -.13* 
Note. HDRS = Hamilton Depression Rating Scale, BDI = Beck Depression Inventory, CVLT = 
California Verbal Learning Test, MSRT = Michigan Spatial Relation Test, COWAT = 
Controlled Oral Word Association Test, WCST = Wisconsin Card Sorting Test.  
*p < .05, **p < .01 two-tailed 
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Table 8. ANCOVA Method: Group Comparisons for Neuropsychological Tests for Healthy 
Comparison, Unmedicated MDD and Medicated MDD Groups Adjusted for Age and Education. 
 
Variable Mdiff1 (SEdiff) F df p Cohen’s d 
       
Processing Speed Composite   4.65 2, 323 .010   
HC vs. uMDD -0.15 (0.12)     .210 0.17 
HC vs. mMDD 0.36 (0.12)     .003 0.41 
uMDD vs. mMDD -0.21 (0.13)     .113 -0.24 
 Purdue Pegboard   2.93 2, 294 .055   
HC vs. uMDD -0.02 (0.14)    .866 -0.02 
HC vs. mMDD 0.33 (0.15)     .030 0.31 
uMDD vs. mMDD -0.35 (0.17)    .035 -0.33 
 Trails A   2.65 2, 268  .072   
HC vs. uMDD 0.12 (0.10)   .227 0.17 
HC vs. mMDD 0.24 (0.11)   .025 0.34 
uMDD vs. mMDD -0.12 (0.12)   .330 -0.16 
 Go Reaction Time   1.67 2, 284 .190   
HC vs. uMDD 0.25 (0.18)   .152 0.20 
HC vs. mMDD 0.28 (0.18)   .119 0.23 
uMDD vs. mMDD -0.03 (0.20)   .891 -0.02 
Attention Composite   3.69 2, 326 .026  
HC vs. uMDD -0.03 (0.10)   .751 -0.04 
HC vs. mMDD 0.23 (0.10)   .017 0.32 
uMDD vs. mMDD -0.26 (0.11)   .017 -0.36 
 Digit Span Forward    3.60 2, 268 .029   
HC vs. uMDD -0.14 (0.09)   .129 -0.22 
HC vs. mMDD 0.15 (0.10)   .127 0.23 
uMDD vs. mMDD -0.29 (0.11)   .008 -0.44 
 CVLT-II Trial 1   3.35 2, 321 .036   
HC vs. uMDD 0.12 (0.15)   .455 0.10 
HC vs. mMDD 0.40 (0.16)   .010 0.35 
uMDD vs. mMDD -0.29 (0.18)   .104 -0.25 
 Go Accuracy   1.88 2, 280 .155   
HC vs. uMDD -0.11 (0.15)   .461 -0.10 
HC vs. mMDD 0.22 (0.16)   .157 0.20 
uMDD vs. mMDD -0.34 (0.18)   .059 -0.31 
Learning-Memory Composite    4.59 2, 324 .011   
HC vs. uMDD  0.01 (0.93)   .968  0.00 
HC vs. mMDD 0.27 (0.93)   .005 0.38 
uMDD vs. mMDD -0.26 (0.11)   .014 -0.37 
 CVLT-II Total 1-5    1.63 2, 321 .198   
HC vs. uMDD 0.10 (0.11)   .394 0.01 
HC vs. mMDD 0.21 (0.12)   .074 0.24 
uMDD vs. mMDD -0.11 (0.13)   .403 -0.13 
(table continues) 
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Variable Mdiff1 (SEdiff) F df p Cohen’s d 
 CVLT-II LDFR    0.96 2, 319 .085  
HC vs. uMDD -0.06 (0.11)   .566 -0.08 
HC vs. mMDD 0.10 (0.11)   .333 0.13 
uMDD vs. mMDD -0.16 (0.12)   -.174 -0.21 
 MSRT Total 1-5    0.88 2, 219 .418   
HC vs. uMDD 0.10 (0.16)   .557 -0.10 
HC vs. mMDD 0.18 (0.14)   .189 0.20 
uMDD vs. mMDD -0.09 (0.17)   .612 -0.09 
 MSRT LDFR   1.04 2, 218 .354   
HC vs. uMDD 0.23 (0.16)   .153 0.25 
HC vs. mMDD 0.09 (0.14)   .515 0.10 
uMDD vs. mMDD 0.14 (0.17)   .412 0.15 
Working Memory Composite   0.70 2, 318 .497  
HC vs. uMDD 0.09 (0.10)   .383 0.12 
HC vs. mMDD 0.10 (0.10)   .293 0.14 
uMDD vs. mMDD -0.02 (0.11)   .868 -0.02 
 Digit Span Backward   1.18 2, 269 .310   
HC vs. uMDD 0.01 (0.09)   .916 -0.01 
HC vs. mMDD 0.13 (0.09)   .143 0.22 
uMDD vs. mMDD -0.12 (0.10)   .224 -0.20 
 No-Go Accuracy   0.07 2, 280 .931   
HC vs. uMDD 0.04 (0.12)   .741 0.05 
HC vs. mMDD 0.04 (0.12)   .776 0.04 
uMDD vs. mMDD -0.01 (0.14)   .972 -0.01 
Executive Function Composite   0.01 2, 279 .993   
HC vs. uMDD 0.01 (0.10)   .908 -0.02 
HC vs. mMDD 0.01 (0.11)   .944 0.01 
uMDD vs. mMDD  0.01 (0.12)   .970 -0.01 
 COWAT    0.32 2, 287 .730   
HC vs. uMDD -0.11 (0.14)   .443 -0.11 
HC vs. mMDD -0.07 (0.15)   .661 -0.07 
buMDD vs. mMDD -0.04 (0.17)   .805 -0.04 
 Trails B   1.05 2, 288 .008   
HC vs. uMDD 0.11 (0.08)   .176 0.19 
HC vs. mMDD 0.08 (0.09)   .343 0.14 
uMDD vs. mMDD 0.03 (0.08)   .747 0.05 
 WCST Perseverative Errors    0.52 2, 243 .597   
HC vs. uMDD 0.85 (0.23)   .714 -0.05 
HC vs. mMDD 0.26 (0.25)   .311 0.16 
uMDD vs. mMDD -0.17 (0.28)   .542 -0.11 
 
Note. LDFR = Long Delay Free Recall, CVLT = California Verbal Learning Test, MSRT = 
Michigan Spatial Relation Test, COWAT = Controlled Oral Word Association Test, WCST = 
Wisconsin Card Sorting Test.  
1. Mdiff = Mean difference of adjusted means. 
  
Table 9a. Matched-Samples Method: Descriptive Statistics for Demographic Characteristics and Neuropsychological Tests for 
Healthy Comparison, Unmedicated MDD and Medicated MDD Groups. 
 
 Healthy Comparison v. uMDD  Healthy Comparison v. mMDD  uMDD v. mMDD 
 HC 
(n = 88) 
uMDD 
(n = 88) 
 HC 
(n = 67) 
mMDD 
(n = 67) 
 uMDD 
(n = 64) 
mMDD 
(n = 64) 
Variable M (SD) M (SD)  M (SD) M (SD)  M (SD) M (SD) 
Age 38.1 (16.2) 38.2 (16.2)  41.1 (16.9) 40.6 (16.2)  40.8 (16.7) 40.8 (17.0) 
Education 15.6 (2.2) 15.4 (2.4)  16.0 (2.1) 16.2 (2.0)  15.9 (2.3) 16.0 (2.2) 
Processing Speed Composite -0.64 (0.87) -0.87 (0.87)  -0.63 (0.78) -1.07 (0.83)  -0.91 (0.92) -1.08 (0.91) 
 Purdue Pegboard -1.61 (1.05) -1.74 (1.01)  -1.51 (0.97) -2.15 (1.11)  -1.65 (0.99) -2.13 (1.12) 
 Trails A 0.25 (0.68) 0.18 (0.74)  0.31 (0.69) 0.08 (0.76)  0.09 (0.77) -0.03 (0.83) 
 Go Reaction Time -0.62 (1.31) -0.91 (1.18)  -0.66 (1.14) -0.86 (1.26)  -1.04 (1.21) -0.90 (1.34) 
Attention Composite -0.03 (0.72) 0.00 (0.76)  -0.04 (0.73) -0.20 (0.81)  0.00 (0.79) -0.23 (0.86) 
 Digit Span Forward  -0.68 (0.70) -0.58 (0.68)  -0.66 (0.70) -0.86 (0.56)  -0.58 (0.70) -0.90 (0.55) 
 CVLT-II Trial 1 0.66 (1.06) 0.54 (1.23)  0.66 (1.14) 0.27 (1.18)  0.47 (1.17) 0.29 (1.20) 
 Go Accuracy -0.24 (1.14) -0.08 (1.03)  -0.32 (1.04) -0.22 (1.22)  -0.07 (1.07) -0.36 (1.38) 
Learning-Memory Composite  0.50 (0.79) 0.43 (0.76)  0.48 (0.82) 0.16 (0.83)  0.43 (0.80) 0.20 (0.80) 
 CVLT-II Total 1-5  0.69 (0.83) 0.56 (0.90)  0.73 (0.84) 0.49 (1.05)  0.56 (0.91) 0.52 (1.02) 
 CVLT-II LDFR  0.57 (0.81) 0.60 (0.79)  0.52 (0.81) 0.44 (0.88)  0.63 (0.79) 0.50 (0.82) 
 MSRT Total 1-5  0.10 (0.92) -0.01 (0.96)  0.01 (0.96) -0.10 (1.07)  -0.04 (0.98) -0.09 (1.09) 
 MSRT LDFR 0.11 (0.97) -0.15 (0.92)  0.05 (0.95) -0.04 (0.99)  -0.23 (0.98) -0.04 (1.00) 
Working Memory Composite -0.51 (0.66) -0.52 (0.78)  -0.47 (0.62) -0.50 (0.70)  -0.56 (0.78) -0.50 (0.76) 
 Digit Span Backward -1.17 (0.68) -1.21 (0.68)  -1.18 (0.69) -1.34 (0.45)  -1.26 (0.65) -1.34 (0.43) 
 No-Go Accuracy 0.14 (0.72) 0.16 (0.88)  0.25 (0.60) 0.26 (0.83)  0.14 (0.82) 0.23 (0.86) 
Executive Function Composite 0.00 (0.78) 0.07 (0.63)  0.04 (0.80) 0.11 (0.67)  0.04 (0.62) 0.05 (0.74) 
 COWAT  0.09 (1.16) 0.31 (0.84)  0.13 (1.25) 0.35 (0.89)  0.28 (0.85) 0.33 (0.88) 
 Trails B 0.50 (0.52) 0.35 (0.55)  0.47 (0.56) 0.38 (0.60)  0.31 (0.55) 0.30 (0.72) 
 WCST Perseverative Errors  -0.54 (1.57) -0.50 (1.39)  -0.44 (1.42) -0.44 (1.61)  -0.50 (1.36) -0.47 (1.54) 
Note. uMDD = unmedicated MDD, mMDD = medicated MDD; CVLT = California Verbal Learning Test, MSRT = Michigan Spatial 
Relation Test, LDFR = Long Delay Free Recall, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card 
Sorting Test. 1. Samples matched for age (+ 5 years) and education (+ 3 years); one pool of HC participants to match clinical groups.
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Table 9b. Matched-Samples1 Method: Group Comparisons of Neuropsychological Tests for 
Healthy Comparison, Unmedicated MDD and Medicated MDD Groups. 
 
Variable Mdiff (SEdiff) t df p Cohen’s d 
       
Processing Speed Composite       
HC vs. uMDD 0.23 (0.13) 1.75 172 .082 0.26 
HC vs. mMDD 0.44 (0.14) 3.17 131 .002 0.55 
uMDD vs. mMDD 0.12 (0.16) 1.02 125 .312 0.13 
 Purdue Pegboard       
HC vs. uMDD 0.12 (0.16) 0.76 158 .452 -0.12 
HC vs. mMDD 0.65 (0.19) 3.37 117 .001 0.62 
uMDD vs. mMDD 0.42 (0.19) 2.43 116 .017 0.41 
 Trails A       
HC vs. uMDD 0.07 (0.12) 0.63 150 .527 0.10 
HC vs. mMDD 0.23 (0.14) 1.66 107 .100 0.32 
uMDD vs. mMDD 0.08 (0.15) 0.82 104 .415 0.10 
 Go Reaction Time       
HC vs. uMDD 0.29 (0.20) 1.43 148 .156 0.29 
HC vs. mMDD 0.19 (0.23) 0.85 108 .397 0.16 
uMDD vs. mMDD -0.20 (0.24) -0.54 106 .588 0.16 
Attention Composite       
HC vs. uMDD -0.03 (0.11) -0.30 174 .763 -0.04 
HC vs. mMDD 0.16 (0.13) 1.12 132 .237 0.20 
uMDD vs. mMDD 0.20 (0.12) 1.58 126 .117 -0.24 
 Digit Span Forward        
HC vs. uMDD -0.09 (0.11) -0.83 149 .407 -0.13 
HC vs. mMDD 0.20 (0.12) 1.63 107 .107 0.31 
uMDD vs. mMDD 0.30 (0.12) 2.57 103 .012 -0.48 
 CVLT-II Trial 1       
HC vs. uMDD 0.12 (0.17) 0.69 172 .489 0.10 
HC vs. mMDD 0.39 (0.20) 1.91 130 .059 0.33 
uMDD vs. mMDD 0.16 (0.21) 0.82 125 .414 -0.13 
 Go Accuracy       
HC vs. uMDD -0.16 (0.18) -0.93 148 .356 -0.02 
HC vs. mMDD -0.10 (0.22) -0.45 108 .652 -0.09 
uMDD vs. mMDD 0.21 (0.22) 1.24 106 .217 -0.18 
Learning-Memory Composite        
HC vs. uMDD 0.07 (0.12) 0.59 173 .557 0.09 
HC vs. mMDD 0.32 (0.14) 2.25 132 .026 0.39 
uMDD vs. mMDD 0.21 (0.14) 1.64 125 .103 -0.27 
 CVLT-II Total 1-5        
HC vs. uMDD 0.13 (0.13) 1.01 172 .312 0.15 
HC vs. mMDD 0.24 (0.17) 1.47 130 .144 0.25 
uMDD vs. mMDD 0.02 (0.17) 0.25 125 .806 -0.02 
(table continues) 
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Variable Mdiff (SEdiff) t df p Cohen’s d 
 CVLT-II LDFR        
HC vs. uMDD -0.03 (0.12) -0.24 171 .810 -0.04 
HC vs. mMDD 0.08 (0.15) 0.33 130 .593 0.09 
uMDD vs. mMDD 0.10 (0.14) 0.90 124 .370 -0.13 
 MSRT Total 1-5        
HC vs. uMDD 0.11 (0.19) 0.58 95 .563 0.12 
HC vs. mMDD 0.11 (0.21) 0.54 96 .591 0.11 
uMDD vs. mMDD 0.03 (0.23) 0.22 87 .826 -0.03 
 MSRT LDFR       
HC vs. uMDD 0.26 (0.19) 1.33 95 .188 0.27 
HC vs. mMDD 0.08 (0.20) 0.42 95 .677 0.09 
uMDD vs. mMDD -0.19 (0.22) -0.84 86 .403 0.19 
Working Memory Composite       
HC vs. uMDD 0.01 (0.11) 0.11 169 .912 0.02 
HC vs. mMDD 0.03 (0.12) 0.24 129 .807 0.04 
uMDD vs. mMDD -0.08 (0.14) -0.49 121 .625 0.10 
 Digit Span Backward       
HC vs. uMDD 0.05 (0.11) 0.41 150 .682 -0.07 
HC vs. mMDD 0.16 (0.11) 1.39 107 .166 0.27 
uMDD vs. mMDD 0.07 (0.11) 0.74 104 .460 -0.11 
 No-Go Accuracy       
HC vs. uMDD -0.02 (0.13) -0.15 148 .879 0.02 
HC vs. mMDD -0.01 (0.14) -0.08 108 .939 -0.01 
uMDD vs. mMDD -0.12 (0.16) -0.57 106 .569 0.14 
Executive Function Composite       
HC vs. uMDD -0.07 (0.11) -0.57 156 .567 -0.09 
HC vs. mMDD -0.08 (0.14) -0.55 112 .583 -0.10 
uMDD vs. mMDD 0.02 (0.13) -0.03 106 .976 0.04 
 COWAT        
HC vs. uMDD -0.22 (0.16) -1.37 155 .172 -0.22 
HC vs. mMDD -0.21 (0.22) -0.99 105 .326 -0.19 
buMDD vs. mMDD -0.05 (0.18) -0.28 99 .777 -0.07 
 Trails B       
HC vs. uMDD 0.16 (0.09) 1.80 150 .074 0.29 
HC vs. mMDD 0.08 (0.11) 0.75 107 .456 0.14 
uMDD vs. mMDD 0.05 (0.11) 0.08 104 .937 0.08 
 WCST Perseverative Errors        
HC vs. uMDD -0.04 (0.25) -0.16 142 .872 -0.03 
HC vs. mMDD 0.01 (0.31) 0.20 95 .984 0.00 
uMDD vs. mMDD -0.03 (0.30) -0.09 91 .927 0.02 
 
Note. Mdiff = Mean difference; HC = healthy comparison, uMDD = unmedicated MDD, mMDD 
= medicated MDD; CVLT = California Verbal Learning Test, MSRT = Michigan Spatial 
Relation Test, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card 
Sorting Test. 1. Samples matched for age (+5 years) and education (+ 3 years). 
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Table 10. Regression Line Method1: Group Comparisons of Standardized Predicted-Residuals 
on Neuropsychological Tests Adjusted for Age and Education Based on Healthy Comparison 
Group 
Variable Mdiff (SEdiff) F or t df p Cohen’s d 
Processing Speed Composite     4.26 2, 325 .015   
HC vs. uMDD 0.14 (0.11) 1.26 237 .210 0.17 
HC vs. mMDD 0.34 (0.12) 2.92 238 .004 0.39 
uMDD vs. mMDD 0.20 (0.13) 1.45 175 .149 -0.22 
 Purdue Pegboard     2.94 2, 296 .054   
HC vs. uMDD -0.02 (0.15) -0.15 217 .878 -0.02 
HC vs. mMDD 0.32 (0.15) 2.14 212 .034 0.30 
uMDD vs. mMDD 0.34 (0.15) 2.20 163 .029 -0.34 
 Trails A     2.33 2, 270 .099   
HC vs. uMDD 0.13 (0.09) 1.37 200 .172 0.20 
HC vs. mMDD 0.22 (0.10) 2.14 194 .034 0.32 
uMDD vs. mMDD 0.09 (0.13) 0.71 147 .481 -0.12 
 Go Reaction Time     1.67 2, 282 .190   
HC vs. uMDD 0.25 (0.17) 1.46 209 .145 0.21 
HC vs. mMDD 0.28 (0.18) 1.54 206 .126 0.22 
uMDD vs. mMDD 0.03 (0.20) 0.13 149 .899 -0.02 
Attention Composite     4.28 2, 328 .015  
HC vs. uMDD 0.04 (0.09) -0.41 240 .684 -0.05 
HC vs. mMDD 0.24 (0.10) 2.55 240 .011 0.34 
uMDD vs. mMDD 0.28 (0.11) 2.52 176 .013 -0.38 
 Digit Span Forward      2.88 2, 270 .058   
HC vs. uMDD -0.13 (0.10) -1.37 198 .171 -0.20 
HC vs. mMDD 0.12 (0.09) 1.31 195 .191 0.19 
uMDD vs. mMDD 0.25 (0.11) 2.38 147 .018 -0.39 
 CVLT-II Trial 1     3.56 2, 323 .030   
HC vs. uMDD 0.11 (0.16) 0.72 236 .474 0.10 
HC vs. mMDD 0.41 (0.15) 2.65 236 .009 0.35 
uMDD vs. mMDD 0.30 (0.17) 1.75 174 .081 -0.26 
 Go Accuracy     2.53 2, 282 .082   
HC vs. uMDD -0.12 (0.14) -0.89 209 .374 -0.13 
HC vs. mMDD 0.26 (0.16) 1.60 206 .111 0.23 
uMDD vs. mMDD 0.38 (0.19) 2.06 131.1a .041 -0.33 
Learning-Memory Composite      4.93 2, 326 .008   
HC vs. uMDD 0.00 (0.09) -0.01 238 .993 0.00 
HC vs. mMDD 0.27 (0.09) 2.90 239 .004 0.39 
uMDD vs. mMDD 0.27 (0.11) 2.55 175 .012 -0.38 
 CVLT-II Total 1-5      1.77 2, 323 .171   
HC vs. uMDD 0.09 (0.11) 0.88 236 .378 0.12 
HC vs. mMDD 0.21 (0.11) 1.86 236 .065 0.25 
uMDD vs. mMDD 0.12 (0.14) 0.88 165.4a .381 -0.13 
(table continues) 
         
66 
 
 
Variable Mdiff (SEdiff) F or t df p Cohen’s d 
 CVLT-II LDFR  0.98 2, 321 .378 
HC vs. uMDD -0.06 (0.10) -0.63 234 .531 -0.08 
HC vs. mMDD 0.10 (0.11) 0.95 235 .345 0.13 
uMDD vs. mMDD 0.16 (0.13) 1.30 163.7a .195 -0.20 
 MSRT Total 1-5      0.96 2, 221 .384   
HC vs. uMDD 0.07 (0.16) 0.45 147 .655 0.08 
HC vs. mMDD 0.19 (0.14) 1.37 176 .174 0.21 
uMDD vs. mMDD 0.12 (0.17) 0.70 119 .485 -0.13 
 MSRT LDFR     1.06 2, 220 .348   
HC vs. uMDD 0.23 (0.16) 1.45  147 .150 0.26 
HC vs. mMDD 0.10 (0.14) 0.71 175 .477 0.11 
uMDD vs. mMDD -0.13 (0.16) -0.79 118 .434 0.15 
Working Memory Composite     0.57 2, 320 .567   
HC vs. uMDD 0.08 (0.10) 0.84 234 .403 0.11 
HC vs. mMDD 0.09 (0.09) 0.96 235 .340 0.13 
uMDD vs. mMDD 0.01 (0.11) 0.05 171 .963 -0.01 
 Digit Span Backward     0.87 2, 282 .419   
HC vs. uMDD 0.01 (0.09) 0.15 199 .884 0.02 
HC vs. mMDD 0.11 (0.08) 1.35 195 .178 0.20 
uMDD vs. mMDD 0.10 (0.10) 1.02 137.3a .311 -0.17 
 No-Go Accuracy     0.07 2, 282 .931   
HC vs. uMDD 0.04 (0.12) 0.34 209 .734 0.05 
HC vs. mMDD 0.03 (0.12) 0.29 206 .773 0.04 
uMDD vs. mMDD -0.01 (0.14) -0.05 149 .964 0.01 
Executive Function Composite     0.00 2, 281 .997   
HC vs. uMDD 0.01 (0.09) 0.08 208 .934 0.01 
HC vs. mMDD 0.00 (0.11) 0.04 204 .968 0.01 
uMDD vs. mMDD -0.01 (0.12) -0.03 150 .977 0.00 
 COWAT      0.36 2, 269 .695   
HC vs. uMDD -0.12 (0.14) -0.84 207 .400 -0.12 
HC vs. mMDD -0.05 (0.15) -0.32 193 .752 -0.05 
buMDD vs. mMDD 0.07 (0.12) 0.46 138 .645 -0.08 
 Trails B     0.98 2, 270 .378   
HC vs. uMDD -0.11 (0.07) 1.45 199 .149 0.21 
HC vs. mMDD 0.08 (0.08) 0.93 194 .354 0.14 
uMDD vs. mMDD -0.03 (0.10) -0.29 147 .769 0.05 
 WCST Perseverative Errors      0.50 2, 245 .610   
HC vs. uMDD -0.09 (0.21) 0.41 190 .683 0.06 
HC vs. mMDD 0.25 (0.25) 0.98 174 .330 0.16 
uMDD vs. mMDD 0.16 (0.30) 0.54 188.8a .588 -0.10 
Note. HC = Healthy Control, uMDD = Unmedicated MDD, mMDD = Medicated MDD, CVLT 
= California Verbal Learning Test, MSRT = Michigan Spatial Relation Test, LDFR = Long 
Delay Free Recall, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card 
Sorting Test. 1. Fleiss & Tanur, 1973. 
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Table 11. Propensity Matching Estimators Method: Group Comparisons of Propensity Scores on 
Neuropsychological Tests Adjusted for Age and Education  
Variable Z N p Cohen’s d 
     
Processing Speed Composite       
HC vs. uMDD -1.08 239 .278 0.14 
HC vs. mMDD -2.69 240 .007 0.35 
uMDD vs. mMDD -2.28 177 .023 -0.35 
 Purdue Pegboard       
HC vs. uMDD 0.43 219 .666 -0.06 
HC vs. mMDD -1.46 214  .143 0.20 
uMDD vs. mMDD -2.15 165 .032 -0.34 
 Trails A       
HC vs. uMDD -0.61 201 .542 0.08 
HC vs. mMDD -1.65 196 .099 0.22 
uMDD vs. mMDD -0.74 149 .458 -0.11 
 Go Reaction Time       
HC vs. uMDD -1.24 211 .214 0.17 
HC vs. mMDD -1.53 208 .127 0.21 
uMDD vs. mMDD -0.78 151 .434 -0.13 
Attention Composite       
HC vs. uMDD 0.84 242 .403 -0.11 
HC vs. mMDD -1.88 242 .060 0.24 
uMDD vs. mMDD -2.31 178 .021 -0.35 
 Digit Span Forward        
HC vs. uMDD 1.77 201 .077 -0.25 
HC vs. mMDD -1.75 197 .080 0.25 
uMDD vs. mMDD -3.41 150 .001 -0.58 
 CVLT-II Trial 1       
HC vs. uMDD -0.46 238 .645 0.06 
HC vs. mMDD -2.30 238 .022 0.22 
uMDD vs. mMDD -1.54 176 .123 -0.23 
 Go Accuracy       
HC vs. uMDD -0.27 211 .787 0.04 
HC vs. mMDD -0.37 208 .714 0.05 
uMDD vs. mMDD -0.14 151 .892 -0.02 
Learning-Memory Composite        
HC vs. uMDD 0.27 240 .790 -0.04 
HC vs. mMDD -2.55 241 .011 0.33 
uMDD vs. mMDD -2.45 177 .014 -0.38 
 CVLT-II Total 1-5        
HC vs. uMDD -0.42 238 .674 0.05 
HC vs. mMDD -1.65 238 .099 0.22 
uMDD vs. mMDD -0.65 176 .517 -0.10 
   (table continues) 
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Variable Z N p Cohen’s d 
          CVLT-II LDFR  
HC vs. uMDD 0.75 236 .455 -0.10 
HC vs. mMDD -0.97 237 .331 0.13 
uMDD vs. mMDD -1.02 175 .309 -0.16 
 MSRT Total 1-5        
HC vs. uMDD 0.16 149 .873 -0.02 
HC vs. mMDD -0.73 178  .467 0.10 
uMDD vs. mMDD -0.77 121 .440 -0.12 
 MSRT LDFR       
HC vs. uMDD -1.15 149 .252 0.15 
HC vs. mMDD -0.25 177 .805 0.03 
uMDD vs. mMDD 0.51 120 .612 0.08 
Working Memory Composite       
HC vs. uMDD -0.49 236 .624 0.06 
HC vs. mMDD -0.90 237 .369 0.12 
uMDD vs. mMDD -0.21 173 .834 -0.03 
 Digit Span Backward       
HC vs. uMDD -0.06 201 .954 0.01 
HC vs. mMDD -1.72 197 .086 0.25 
uMDD vs. mMDD -1.01 150 .313 -0.17 
 No-Go Accuracy       
HC vs. uMDD -0.29 211 .772 0.04 
HC vs. mMDD -0.43 208 .664 0.06 
uMDD vs. mMDD -0.17 151 .864 -0.03 
Executive Function Composite       
HC vs. uMDD 0.09 210 .929 -0.01 
HC vs. mMDD -0.04 206 .967 0.01 
uMDD vs. mMDD -0.24 152 .814 -0.04 
 COWAT        
HC vs. uMDD 0.87 209 .387 -0.12 
HC vs. mMDD 0.47 195 .636 -0.07 
uMDD vs. mMDD -0.12 140 .902 -0.02 
 Trails B       
HC vs. uMDD -0.84 201 .403 0.11 
HC vs. mMDD 0.22 196 .824 -0.03 
uMDD vs. mMDD 0.98 177 .329 0.15 
 WCST Perseverative Errors        
HC vs. uMDD -0.33 192 .742 0.05 
HC vs. mMDD -1.30 176 .192 0.20 
uMDD vs. mMDD -1.11 128 .267 -0.20 
Note. HC = Healthy Control, uMDD = Unmedicated MDD, mMDD = Medicated MDD, CVLT 
= California Verbal Learning Test, MSRT = Michigan Spatial Relation Test, LDFR = Long 
Delay Free Recall, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card 
Sorting Test.  
 Table 12. Group Comparisons on Neuropsychological Tests for Healthy Controls, Unmedicated MDD and Medicated MDD: 
Unadjusted ANOVA, and Age- and Education-Adjusted ANCOVA, Matched Sample, Regression Line, and Propensity Score Methods. 
  ANOVA ANCOVA Matched  Sample Regression Line Propensity Score 
Variable df 1 p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d 
Processing Speed Composite 2, 325 .00  .01   --  .02   --  
HC vs. uMDD 237 .44 0.10 .21 0.17 .08 0.26 .21 0.17 .28 0.14 
HC vs. mMDD 238 .00 0.52 .00 0.41 .00 0.55 .00 0.39 .01 0.35 
uMDD vs. mMDD 175 .00 -0.43 .11 -0.24 .31 0.13 .15 -0.22 .02 -0.35 
 Purdue Pegboard 2, 296 .00   .06   --  .05  --   
HC vs. uMDD 217 .59 -0.08 .87 -0.02 .45 -0.12 .88 -0.02 .67 -0.06 
HC vs. mMDD 212 .00 0.44 .03 0.31 .00 0.62 .03 0.30  .14 0.20 
uMDD vs. mMDD 163 .00 -0.57 .04 -0.33 .02 0.41 .03 -0.34 .03 -0.34 
 Trails A 2, 270 .00   .07   --  .10  --   
HC vs. uMDD 200 .56 0.08 .23 0.17 .53 0.10 .17 0.20 .54 0.08 
HC vs. mMDD 194 .00 0.48 .03 0.34 .10 0.32 .03 0.32 .10 0.22 
uMDD vs. mMDD 147 .02 -0.38 .33 -0.16 .42 0.10 .48 -0.12 .46 -0.11 
 Go Reaction Time 2, 282 .07   .19   --  .19  --   
HC vs. uMDD 209 .27 0.16 .15 0.20 .16 0.29 .15 0.21 .21 0.17 
HC vs. mMDD 206 .03 0.32 .12 0.23 .40 0.16 .13 0.22 .13 0.21 
uMDD vs. mMDD 149 .27 -0.18 .89 -0.02 .59 0.16 .90 -0.02 .43 -0.13 
Attention Composite 2, 328 .00   .03  --  .02  --   
HC vs. uMDD 240 .50 -0.09 .75 -0.04 .76 -0.04 .68 -0.05 .40 -0.11 
HC vs. mMDD 240 .00 0.44 .02 0.32 .24 0.20 .01 0.34 .06 0.24 
uMDD vs. mMDD 176 .00 -0.51 .02 -0.36 .12 -0.24 .01 -0.38 .02 -0.35 
 Digit Span Forward  2, 270 .01   .03   --  .06  --   
HC vs. uMDD 198 .12 -0.20 .13 -0.22 .41 -0.13 .17 -0.20 .08 -0.25 
HC vs. mMDD 195 .06 0.28 .13 0.23 .11 0.31 .19 0.19 .08 0.25 
uMDD vs. mMDD 147 .00 -0.44 .01 -0.44 .01 -0.48 .02 -0.39 .00 -0.58 
 CVLT-II Trial 1 2, 323 .00   .04   --  .03  --   
HC vs. uMDD 236 .70 0.05 .46 0.10 .49 0.10 .47 0.10 .65 0.06 
HC vs. mMDD 236 .00 0.45 .01 0.35 .06 0.33 .01 0.35 .02 0.22 
uMDD vs. mMDD 174 .01 -0.41 .10 -0.25 .41 -0.13 .08 -0.26 .12 -0.23 
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  ANOVA ANCOVA Matched  Sample Regression Line Propensity Score 
Variable df 1 p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d 
              
 Go Accuracy 2, 282 .03   .16   --  .08  --  
HC vs. uMDD 209 .30 -0.15 .46 -0.10 .36 -0.02 .37 -0.13 .79 0.04 
HC vs. mMDD 206 .05 0.29 .16 0.20 .65 -0.09 .11 0.23 .71 0.05 
uMDD vs. mMDD 131.1a .02 -0.40 .06 -0.31 .22 -0.18 .04 -0.33 .89 -0.02 
Learning-Memory Composite  2, 326 .00   .01   --  .01  --   
HC vs. uMDD 238 .69 -0.05 .97  0.00 .56 0.09 .99 0.00 .79 -0.04 
HC vs. mMDD 239 .00 0.50 .01 0.38 .03 0.39 .00 0.39 .01 0.33 
uMDD vs. mMDD 175 .00 -0.56 .01 -0.37 .10 -0.27 .01 -0.38 .01 -0.38 
 CVLT-II Total 1-5  2, 323 .02   .20   --  .17  --   
HC vs. uMDD 236 .67 0.06 .39 0.01 .31 0.15 .38 0.12 .67 0.05 
HC vs. mMDD 236 .01 0.36 .07 0.24 .14 0.25 .07 0.25 .10 0.22 
uMDD vs. mMDD 165.4a .05 -0.30 .40 -0.13 .81 -0.02 .38 -0.13 .52 -0.10 
 CVLT-II LDFR  2, 321 .55   .09  --  .38  --  
HC vs. uMDD 234 .34 -0.13 .57 -0.08 .81 -0.04 .53 -0.08 .46 -0.10 
HC vs. mMDD 235 .06 0.25 .33 0.13 .59 0.09 .35 0.13 .33 0.13 
uMDD vs. mMDD 163.7a .02 -0.37 .17 -0.21 .37 -0.13 .20 -0.20 .31 -0.16 
 MSRT Total 1-5  2, 221 .21   .42   --  .38  --   
HC vs. uMDD 147 .88 -0.03 .56 -0.10 .56 0.12 .66 0.08 .87 -0.02 
HC vs. mMDD 176 .12 0.24 .19 0.20 .59 0.11 .17 0.21  .47 0.10 
uMDD vs. mMDD 119 .17 -0.26 .61 -0.09 .83 -0.03 .49 -0.13 .44 -0.12 
 MSRT LDFR 2, 220 .55   .35   --  .35  --   
bHC vs. uMDD 147 .53 -0.11 .15 0.25 .19 0.27 .15 0.26 .25 0.15 
bHC vs. mMDD 175 .30 0.16 .52 0.10 .68 0.09 .48 0.11 .81 0.03 
buMDD vs. mMDD 118 .78 -0.05 .41 0.15 .40 0.19 .43 0.15 .61 0.08 
Working Memory Composite 2, 320 .35   .50  --  .57  --   
HC vs. uMDD 234 .47 0.10 .38 0.12 .91 0.02 .40 0.11 .62 0.06 
HC vs. mMDD 235 .14 0.20 .29 0.14 .81 0.04 .34 0.13 .37 0.12 
uMDD vs. mMDD 171 .55 -0.09 .87 -0.02 .63 0.10 .96 -0.01 .83 -0.03 
           
70 
  
  ANOVA ANCOVA Matched  Sample Regression Line Propensity Score 
Variable df 1 p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d p Cohen’s d 
 Digit Span Backward 2, 282 .07   .31   --  .42  --   
HC vs. uMDD 199 .88 -0.02 .92 -0.01 .68 -0.07 .88 0.02 .95 0.01 
HC vs. mMDD 195 .03 0.23 .14 0.22 .17 0.27 .18 0.20 .09 0.25 
uMDD vs. mMDD 137.3a .04 -0.34 .22 -0.20 .46 -0.11 .31 -0.17 .31 -0.17 
 No- Go Accuracy  2, 282           
HC vs. uMDD 209 .75 0.04 .74 0.05 .88 0.02 .73 0.05 .77 0.04 
HC vs. mMDD 206 .72 0.05 .78 0.04 .94 -0.01 .77 0.04 .66 0.06 
uMDD vs. mMDD 149 .97 -0.01 .97 -0.01 .57 0.14 .96 0.01 .86 -0.03 
Executive Function Composite 2, 281 .24   .99   --  .99  --   
HC vs. uMDD 208 .56 -0.08 .91 -0.02 .57 -0.09 .93 0.01 .93 -0.01 
HC vs. mMDD 204 .23 0.18 .94 0.01 .58 -0.10 .97 0.01 .97 0.01 
uMDD vs. mMDD 150 .12 -0.25 .97 -0.01 .98 0.04 .98 0.00 .81 -0.04 
 COWAT  2, 269 .62   .73   --  .70  --   
HC vs. uMDD 207 .35 -0.14 .44 -0.11 .17 -0.22 .40 -0.12 .39 -0.12 
HC vs. mMDD 193 .90 -0.02 .66 -0.07 .33 -0.19 .75 -0.05 .64 -0.07 
uMDD vs. mMDD 138 .45 -0.13 .81 -0.04 .78 -0.07 .65 -0.08 .90 -0.02 
 Trails B 2, 270 .06   .01   --  .38  --   
HC vs. uMDD 199 .60 0.08 .18 0.19 .07 0.29 .15 0.21 .40 0.11 
HC vs. mMDD 194 .03 0.33 .34 0.14 .46 0.14 .35 0.14 .82 -0.03 
uMDD vs. mMDD 147 .11 -0.26 .75 0.05 .94 0.08 .77 0.05 .33 0.15 
 WCST Perseverative 
Errors  
2, 245 .33   .60   --  .61  --   
HC vs. uMDD 190 .85 -0.03 .71 -0.05 .87 -0.03 .68 0.06 .74 0.05 
HC vs. mMDD 174 .21 0.20 .31 0.16 .98 0.00 .33 0.16 .19 0.20 
uMDD vs. mMDD 188.8a .23 -0.23 .54 -0.11 .93 0.02 .59 -0.10 .27 -0.20 
 
Note. HC = Healthy Controls, uMDD = unmedicated MDD, mMDD = medicated MDD; CVLT = California Verbal Learning Test, 
MSRT = Michigan Spatial Relation Test, COWAT = Controlled Oral Word Association Test, WCST = Wisconsin Card Sorting Test. 
a. Levene’s correction for heterogeneity of variance. df = degrees of freedom for ANOVA or t test. Matched-sample analyses df varied 
by contrast pair: HC-uMDD (176), HC-mMDD (134), uMDD-mMDD (126). 
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Individuals with Major Depressive Disorder (MDD) frequently experience cognitive 
decrements in addition to mood impairments. Ironically, antidepressant medications used to treat 
depression may have adverse effects on cognitive functioning. It is imperative to understand the 
relative cognitive costs of antidepressants when considering the treatment of MDD patients. 
Furthermore, observational studies of depression are challenged by problems of systematically 
confounded variables. Researchers are often faced with difficulties in managing this issue and 
opt to either ignore the problem, alter their sample, or use inappropriate statistical methods (e.g., 
Analysis of Covariance) due to a limited understanding of acceptable solutions.  It is important to 
provide researchers with the access to general knowledge of methods to manage systematic 
covariates in order to aid in effective and appropriate decision-making. 
Participants included 178 adults with MDD (89 unmedicated-uMDD, 89 medicated- 
mMDD) and 153 healthy comparison (HC) adults who were evaluated for performance in 
several domains of cognition. The three groups were significantly different on age (mMDD 
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group was oldest) but equivalent on education. The MDD groups were equivalent in years of 
illness, differed on depression severity (uMDD more severe than mMDD).  
Univariate analyses of variance (ANOVAs) indicated that performance among the groups 
was significantly different for measures of processing speed, attention, and some aspects of the 
learning and memory domain. However, the groups were generally equivalent on measures of 
working memory and executive functioning domains. Post hoc analyses using simple contrasts 
indicated that the significant were generally driven by worse performance for mMDD groups 
compared to uMDD and HCs.  Exploratory analyses accounting for age and education included 
Analysis of Covariance (ANCOVA), Matched-samples, Regression-residuals, and Propensity 
Score Analysis (PSA). Overall, the pattern of findings was constant across methods, with 
relatively stable effect sizes for significant results. However, effect sizes for general (significant 
and non-significant) results varied by method. 
Antidepressants used to treat MDD improve dispositional symptoms of depression but 
have adverse effects on some areas of cognition. Comparing the effect sizes may be useful to 
clinicians and researchers in distinguishing cognitive effects of medication separately from those 
associated with MDD. Furthermore, employing the proper methods to address systematic 
confounds (e.g., age and education) are essential to maintain sound research and to promote 
effective antidepressant treatment. Statistical solutions that are theoretically acceptable to use in 
order to address systematic covariates are discussed. Both the beneficial effects on depressive 
symptoms and adverse effects on cognition should be considered by practitioners and consumers 
when making treatment decisions. 
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